
Novavax
Novavax, Inc. is a biotechnology company founded in 1987 and headquartered in Gaithersburg, Maryland, that discovers, develops…
Expert article
Novavax, Inc. is a biotechnology company founded in 1987 and headquartered in Gaithersburg, Maryland, that discovers, develops, and commercializes recombinant protein nanoparticle vaccines to protect against serious infectious diseases. The company's proprietary platform integrates virus-like nanoparticle structures, engineered to mimic viral surfaces for immune recognition, with the Matrix-M adjuvant—a saponin-based enhancer derived from Quillaja saponaria trees—to amplify and prolong antibody and cellular responses without relying on genetic material or live viruses.
Novavax gained prominence during the COVID-19 pandemic with its Nuvaxovid vaccine (NVX-CoV2373), a protein subunit candidate that demonstrated 90% efficacy against symptomatic infection in phase III trials and received U.S. FDA biologics license approval on May 16, 2025, for adults 65 and older and people aged 12 to 64 with at least one high-risk condition, as the sole non-mRNA option available domestically. Backed by up to $1.8 billion in U.S. government funding through Operation Warp Speed, the program nonetheless encountered manufacturing scale-up difficulties and regulatory delays, which postponed widespread deployment and contributed to financial strain amid competition from faster-to-market mRNA vaccines. These challenges, rooted in the complexities of protein production at commercial volumes, highlighted causal limitations in Novavax's pre-pandemic infrastructure but did not preclude eventual authorizations in over 40 countries and empirical evidence of robust immunogenicity.
Beyond COVID-19, Novavax's pipeline targets respiratory pathogens including influenza, respiratory syncytial virus (RSV), and combination products like a COVID-influenza bivalent vaccine, building on prior efforts such as a rabies candidate and lessons from a 2016 RSV phase III setback that necessitated restructuring. As a publicly traded entity (NASDAQ: NVAX), the firm has pursued strategic partnerships, including adjuvant licensing and contract manufacturing, to sustain operations and advance assets amid ongoing post-pandemic revenue from vaccine sales and cost-saving measures yielding $230 million in projected efficiencies.
Corporate Overview
Founding and Headquarters
Novavax, Inc. was incorporated in 1987 under the laws of the State of Delaware as a biotechnology company focused on vaccine development. The firm originated with an emphasis on innovative approaches to infectious disease prevention, operating initially from facilities in the Maryland suburbs outside major biotech clusters like Boston and San Diego.
The company maintains its headquarters in Gaithersburg, Maryland, a hub for life sciences research in the Washington, D.C. metropolitan area, with principal executive offices at 21 Firstfield Road. Novavax conducts significant research and development operations from this location, supplemented by its Novavax AB subsidiary in Uppsala, Sweden, which develops new Matrix adjuvant formulations, manufactures and quality-controls the adjuvant, and supplies it for human use, veterinary use, and partners.
Core Technology Platform
Novavax's core technology platform centers on recombinant protein-based nanoparticles paired with the proprietary Matrix-M adjuvant to elicit immune responses against infectious diseases, particularly respiratory pathogens.
Leadership and Governance
Novavax's executive leadership is headed by John C. Jacobs as President and Chief Executive Officer, a position he has held since January 2023 following Stanley Erck's retirement after 12 years in the role. Jacobs brings over 25 years of experience in commercial, operations, business, and leadership across multiple therapeutic areas. The senior team includes Jim Kelly as Executive Vice President, Chief Financial Officer and Treasurer; Rick Crowley as Executive Vice President, Chief Operations Officer; Mark Casey as Executive Vice President, Chief Legal Officer; Elaine O’Hara as Executive Vice President, Chief Strategy Officer; Silvia Taylor as Executive Vice President, Chief Corporate Affairs Officer and Head of Novavax Sweden; Robert Walker, MD, as Executive Vice President, Head of Research & Development; Ian Watkins as Executive Vice President, Chief Human Resources Officer; and Troy Morgan, JD, as Senior Vice President, Deputy General Counsel & Chief Compliance Officer. Dr. Ruxandra Draghia-Akli's employment as Executive Vice President, Research & Development ended effective March 27, 2026. On March 30, 2026, Novavax named Dr. Robert Walker, previously Chief Medical Officer, Executive Vice President and Head of Research & Development, reporting to CEO John C. Jacobs. On 14 September 2026 FTI Consulting announced that Draghia-Akli had joined the firm as a Senior Advisor in its Healthcare & Life Sciences practice in Brussels.
In May 2025, Novavax eliminated the Chief Operating Officer position held by John Trizzino, who had served in various leadership roles since 2023, to streamline operations and prioritize R&D partnerships amid post-COVID strategic shifts.
The board of directors, responsible for strategic oversight, risk management, and executive compensation, is chaired by David Mott, an independent director since June 2020, who became Chairman of the Board in 2026, with Margaret G. McGlynn, RPh as Vice Chairman. Other current independent directors include Gregg Alton, Richard Douglas, PhD, Rachel King, Charles Newton, Rick Rodgers, MBA, and John Shiver, PhD.
Novavax's governance structure adheres to guidelines that separate the CEO and board chair roles for enhanced independence, with the board overseeing internal controls, ethical standards, and compliance via dedicated committees including audit, compensation, nominating and corporate governance, and research & development. The company maintains a code of conduct, annual compliance program updates per California regulations, and proxy disclosures emphasizing transparency in executive transitions and risk mitigation. As of October 2025, its ISS Governance QualityScore stands at 5, indicating moderate governance risk across audit, board, shareholder rights, and compensation pillars.
Historical Development
Early Years and Pre-Clinical Focus (1987–2010)
Novavax, Inc. was incorporated in 1987 under Delaware law and established its headquarters in Rockville, Maryland. The company's foundational technology centered on Novasome®, a proprietary system of synthetic lipid vesicles engineered for enhanced drug delivery, enabling targeted release and improved bioavailability. Initial applications emphasized non-vaccine therapeutics, including hormone replacement therapies for women's health and anti-infective treatments, reflecting a preclinical and early clinical emphasis on lipid-based formulations to address unmet needs in chronic conditions.
In its hormone replacement programs, Novavax advanced ESTRASORB®, a transdermal estradiol emulsion for alleviating menopausal symptoms such as hot flashes, which progressed to Phase III trials with positive data milestones reported in July 2001 demonstrating skin permeation and estrogen level elevation. Complementing this, ANDROSORB®, a topical testosterone formulation for male hypogonadism, entered preclinical and early development stages. To support commercialization, Novavax acquired Fielding Pharmaceutical Company in December 2000, gaining a national sales force of over 60 representatives focused on obstetricians and gynecologists, though cumulative losses exceeded $87.5 million by year-end 2002 amid ongoing deficits since inception. These efforts highlighted the company's early pivot toward women's health but encountered regulatory and market hurdles, prompting eventual discontinuation.
Parallel preclinical work included Helicore™, a non-antibiotic lipid-structured agent targeting Helicobacter pylori for peptic ulcer treatment, with 1996 clinical data submitted to the FDA showing efficacy in eradication rates, though development halted due to strategic reprioritization. By the mid-2000s, Novavax redirected resources toward vaccine innovation, licensing virus-like particle (VLP) technology from the University of Massachusetts Medical School in March 2007 to produce recombinant protein nanoparticles mimicking viral structures without genetic material. This enabled preclinical evaluation of VLP candidates, including a 2009 study demonstrating protective immune responses in animal models against the reconstructed 1918 H1N1 influenza strain, laying groundwork for adjuvant-enhanced respiratory vaccines. A key U.S. patent for influenza VLP vaccines issued in July 2010 underscored the platform's potential for rapid strain adaptation using baculovirus expression in insect cells.
Respiratory Virus Programs (2010–2019)
In the 2010s, Novavax advanced its virus-like particle (VLP) and nanoparticle platform toward vaccines for key respiratory pathogens, emphasizing respiratory syncytial virus (RSV) and influenza, with the RSV F protein stabilized in its post-fusion conformation as a central antigen target. These efforts built on preclinical work, incorporating the Matrix-M adjuvant to enhance immunogenicity, particularly in vulnerable populations like pregnant women and older adults.
The RSV program initiated clinical evaluation in December 2010, when the U.S. Food and Drug Administration (FDA) cleared Novavax to begin a Phase I trial of its RSV F vaccine candidate in healthy adults, assessing safety and immunogenicity. The trial launched in January 2011, enrolling participants to test escalating doses of the nanoparticle vaccine. Progressing to Phase II, a 2015 dose-ranging study in pregnant women demonstrated robust antibody responses, with 99% of participants achieving measurable anti-F immunoglobulin G levels and efficient transplacental transfer to infants, supporting maternal immunization as a strategy to protect neonates. Another Phase II trial that year evaluated annual re-dosing in older adults previously vaccinated, confirming safety and immunogenicity without evidence of immune interference. In the Phase III Resolve trial (RSV-E-301) of the unadjuvanted 135 µg RSV F vaccine in 11,856 adults aged 60 and older at 60 U.S. sites, which began in November 2015, the vaccine did not meet its primary or secondary efficacy objectives: topline results announced on September 15, 2016 showed vaccine efficacy of −7.9% against moderate-severe RSV lower respiratory tract disease (26 cases on placebo versus 28 on vaccine) and 12.6% against all symptomatic RSV disease, with RSV attack rates roughly a quarter of those seen in the company's Phase 2 trial, which Novavax said indicated a mild RSV season. These results informed the Phase III PREPARE trial, which enrolled approximately 4,636 pregnant women across multiple global sites starting prior to 2017. Topline data released in February 2019 showed the vaccine did not meet its primary efficacy endpoint of preventing medically significant RSV lower respiratory tract infection (LRTI) in infants, achieving 39% efficacy (97.5% confidence interval: -1% to 64%). However, secondary analyses indicated 44% efficacy against RSV LRTI hospitalizations (95% confidence interval: 20% to 62%) and 60% against severe hypoxemia cases, alongside a favorable safety profile with no increased adverse events in mothers or infants through 180 days post-delivery.
Parallel influenza programs leveraged similar nanoparticle technology, with early efforts yielding positive Phase II data for a trivalent seasonal VLP vaccine in older adults in April 2010, demonstrating superior hemagglutination inhibition titers compared to standard egg-based vaccines. In March 2010, interim results from a pivotal study of an H1N1 pandemic VLP vaccine in Mexico confirmed immunogenicity meeting U.S. and European regulatory criteria after a single dose. By 2017, Novavax initiated a Phase I/II trial of NanoFlu, a quadrivalent nanoparticle influenza vaccine adjuvanted with Matrix-M, in older adults (aged 65-85), testing 15 µg and 60 µg doses against licensed comparators. Phase II results in January 2019 showed NanoFlu elicited higher antibody responses and broader cross-reactivity to variant strains than the active control, with a comparable safety profile. This supported advancement to a pivotal Phase III trial in October 2019, targeting accelerated approval based on immunogenicity surrogates.
Novavax also applied its nanoparticle platform to non-respiratory pathogens, developing NVX-EBOV (Ebola GP), a recombinant nanoparticle glycoprotein vaccine adjuvanted with Matrix-M, in response to the 2014-2015 West African Ebola outbreak using the Makona strain sequence. Preclinical nonhuman primate studies showed strong protection against lethal challenges. A Phase 1 clinical trial initiated in February 2015 in Australia yielded top-line results in July 2015 indicating good tolerability and robust immunogenicity. A 2020 dose-ranging Phase 1 trial confirmed strong adjuvanted responses in humans. No further clinical phases were advanced, and the candidate remains unapproved. Exploratory work on human metapneumovirus (hMPV) remained preclinical during this period, with combinations against RSV and hMPV later prioritized post-2019. These programs highlighted Novavax's emphasis on structure-based antigens for conserved epitopes, though challenges like variable efficacy against mild disease underscored limitations in trial endpoints for respiratory vaccines.
COVID-19 Acceleration (2020–2022)
In early 2020, Novavax initiated development of its SARS-CoV-2 vaccine candidate, NVX-CoV2373, leveraging its established nanoparticle platform with the Matrix-M adjuvant to target the spike protein. Preclinical data in animal models showed robust antibody responses and protection against viral challenge, prompting rapid progression to human studies. The first-in-human Phase I/II trial commenced on May 29, 2020, in Australia, enrolling approximately 130 healthy adults to assess safety, immunogenicity, and dosing.
On July 7, 2020, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DOD), through Operation Warp Speed, awarded Novavax $1.6 billion to support large-scale manufacturing of 100 million doses and clinical trials, later expanded to $1.75 billion. This funding enabled accelerated production at risk, prior to efficacy data, and facilitated partnerships including with the Coalition for Epidemic Preparedness Innovations (CEPI) for global access. On July 6, 2022, Novavax and Advanced Technology International, acting for the Medical CBRN Defense Consortium under the former Operation Warp Speed partnership, entered Modification No. 14 to the July 6, 2020 project agreement. It provided for an initial delivery to the U.S. government of approximately 3 million doses of NVX-CoV2373, to be manufactured by Serum Institute of India Private Limited in Pune or at another FDA-approved location, contingent on Emergency Use Authorization, FDA label and artwork approvals and an ACIP recommendation, and for any further deliveries up to an aggregate of 100 million doses depending on U.S. government demand, FDA strain-selection guidance and agreement on price. Additional collaborations, such as manufacturing agreements with FUJIFILM Diosynth Biotechnologies (FDB) for bulk drug substance production—starting at the Morrisville, North Carolina facility in July 2020 for clinical trial supplies and expanding to College Station, Texas, and Billingham, UK sites by August 2020, the latter with capacity for up to 180 million doses annually—alongside technology transfer to the Serum Institute of India for production in emerging markets, underscored efforts to scale output amid global demand.
Clinical advancement intensified with a Phase IIb trial in South Africa starting August 2020, enrolling over 4,400 participants, followed by the U.K. Phase III trial (NOVAXCOV) launch in September 2020 with 15,000 volunteers. The U.K. trial completed enrollment by November 30, 2020, evaluating efficacy against symptomatic disease in a setting dominated by the Alpha variant. Interim results from the U.K. study, reported January 28, 2021, indicated 89.3% efficacy overall (95% CI: 80.2-94.8%) and 100% against moderate/severe disease, with a favorable safety profile including transient reactogenicity. The South African trial, however, yielded 51.0% efficacy (95% CI: 36.4-62.2%) against the Beta variant, highlighting variant-specific immune escape challenges inherent to non-mRNA platforms.
The U.S./Mexico PREVENT-19 Phase III trial, initiated December 2020 under FDA IND, enrolled 29,960 participants by February 22, 2021, but faced delays in primary analysis due to requirements for variant-updated data and manufacturing consistency verification. Manufacturing scale-up encountered hurdles, including reliance on contract manufacturers like Emergent BioSciences and FUJIFILM Diosynth Biotechnologies for antigen production and issues with raw material sourcing for the complex protein process, contrasting faster mRNA rivals. FDB sites contributed to antigen production in 2021 as Novavax scaled up for authorizations and commercial supply, with the UK Billingham site receiving a visit from Prime Minister Boris Johnson on February 13, 2021. Despite these, Novavax achieved initial EU conditional marketing authorization on December 17, 2021, followed by WHO emergency use listing on December 20, 2021, enabling deployments in countries like Indonesia and the Philippines by early 2022. U.S. FDA emergency use authorization came later, on July 13, 2022, after resolving inspection and potency assay concerns.
Key international milestones included:
- September 7, 2021: Agreement with Takeda Pharmaceutical Company to manufacture and provide up to 150 million doses of NVX-CoV2373 to the government of Japan.
- November 1, 2021: Emergency use authorization in Indonesia.
- January 19, 2022: Provisional approval in Australia.
This period marked Novavax's transition from niche respiratory vaccine developer to a key player, with over $2 billion in commitments by 2021, though delivery shortfalls to global initiatives like COVAX—due to trial holds and fill-finish bottlenecks—drew scrutiny over execution amid the protein vaccine's longer lead times. Pooled Phase I-III safety data through 2022 confirmed low rates of serious adverse events (0.3% vaccine-related), supporting its profile for adults, with pediatric extensions in PREVENT-19 showing immunogenicity in ages 12-17 by February 2022.
Technology Platform
Novavax's technology platform centers on recombinant protein nanoparticle vaccines produced via a baculovirus expression vector system in insect cells, paired with the proprietary Matrix-M adjuvant. This enables the formation of virus-like particles (VLPs) or soluble nanoparticles that replicate viral antigen structures, displaying conformational epitopes to provoke targeted humoral and cellular immunity without infectious risks. The platform supports swift adaptation to emerging pathogens through genetic engineering of antigens.
Nanoparticle Assembly and Production Methods
Antigens are encoded in baculovirus vectors and expressed in Spodoptera frugiperda (Sf9) insect cells, allowing scalable fermentation and purification. Post-expression, proteins self-assemble into 20-40 nm nanoparticles, often stabilized—such as the prefusion or postfusion forms of fusion proteins—via structure-based design. Production timelines enable antigen manufacture in 4-6 weeks and full vaccine doses in 8-12 weeks, leveraging detergent disruption and tangential flow filtration for high-yield purification. This eukaryotic system ensures proper glycosylation and folding, contrasting prokaryotic alternatives.
Matrix-M Adjuvant Development
Matrix-M adjuvant originated from Quillaja saponaria Molina saponins, recognized for immunostimulatory activity since their use in veterinary vaccines in the 1920s, though early formulations faced limitations from hemolysis and reactogenicity. Development progressed in the 1980s with immune stimulating complexes (ISCOMs), pioneered by Bror Morein, which integrated crude Quillaja saponins, cholesterol, and phospholipids into 40-nm cage-like structures to enhance CD4+ and CD8+ T-cell responses and antibody production. Refinements by Isconova AB in Sweden in the early 2000s addressed ISCOM constraints like antigen dependency, yielding Matrix-M as an antigen-independent adjuvant composed of purified saponin fractions—primarily Matrix-A (larger, cholesterol-associated, 85%) and Matrix-C (smaller, phospholipid-integrated, 15%)—self-assembled into stable, soluble 40-nm nanoparticles. This formulation promotes lysosomal antigen processing, inflammasome activation, and cytokine release (e.g., IL-2, IFN-γ, IL-12), while disrupting cell membranes to create antigen depots, recruiting antigen-presenting cells such as monocytes and plasmacytoid dendritic cells to lymph nodes, and biasing responses toward Th1 profiles with elevated IFN-γ. These mechanisms enhance cross-presentation, cytotoxic T-lymphocyte activation, and antibody affinity maturation, enabling dose-sparing, broad antigen compatibility, and storage stability at 2–8°C. Following Novavax's 2013 acquisition of Isconova, Matrix-M was integrated into its nanoparticle platform, with preclinical studies (circa 2009–2013) demonstrating superior humoral and cellular responses over alum controls in models like West Nile virus and pandemic influenza. The first human trial, a 2011 Phase I for H5N1 avian influenza, showed 25 μg doses eliciting fourfold hemagglutination inhibition titer rises in 100% of recipients versus 67% without adjuvant, with mild reactogenicity. Manufacturing scale-up, including sustainable Quillaja sourcing and process optimization, supported Novavax's RSV and influenza pipeline, culminating in its key role in NVX-CoV2373, where it contributed to 90.4% Phase III efficacy by boosting neutralizing antibodies and T-cell memory against variants. Ongoing developments target immuno-oncology and combination vaccines. Novavax AB and Novavax Inc. also have pending patent applications on saponin-based (Matrix-M) adjuvant characterization and biodistribution methods, including WO2025088585A1 (PCT published 1 May 2025) and the related U.S. application US20250134995A1 (published 1 May 2025), which build on the same Matrix-M intramuscular biodistribution work reported by Carnrot et al. in Frontiers in Drug Delivery (2023). Novavax also filed PCT application WO2026202855 (international filing date 27 March 2026; publication date 1 October 2026), titled "Protein-based drug products using monoester-free polysorbate detergent," covering compositions with a biological component and polysorbate free of monoesters, related detergent-core nanoparticles, and manufacturing methods. On 16 July 2026 the World Intellectual Property Organization published Novavax, Inc.'s international patent application WO2026152096A1, "Ribonucleic acid compositions having immunogenicity", filed on 12 January 2026 with priority date 10 January 2025 and naming Gale Smith and Nita Patel as inventors. The application discloses immunogenic compositions comprising ribonucleic acids together with saponin-based adjuvants, including combination vaccines, and discusses uses such as compositions directed at cancer neoantigens arising from protein mutations.
Clinical Evidence and Platform Synergies
Clinical trials across influenza, RSV, and SARS-CoV-2 vaccines demonstrate the platform's potency: adjuvanted nanoparticles elicit 5-10-fold higher antibody titers, broader variant neutralization, and superior T-cell responses versus non-adjuvanted comparators. Synergies emerge from nanoparticles' multivalent antigen display amplifying adjuvant effects, yielding durable memory B-cells and heterologous protection, as evidenced by Phase III data showing 90% efficacy against variants and dose-sparing up to 80%. The combination mitigates age-related immunosenescence, supporting applications in elderly and pediatric cohorts.
Vaccine Products and Pipeline
NVX-CoV2373 COVID-19 Vaccine
NVX-CoV2373 is a recombinant protein-based COVID-19 vaccine developed by Novavax, consisting of nanoparticle-formulated SARS-CoV-2 spike protein stabilized in a prefusion conformation, adjuvanted with saponin-based Matrix-M to enhance immune response. The vaccine targets the ancestral Wuhan strain but has been updated for variants, including the 2025-2026 formula incorporating JN.1 lineage components for broader neutralization.
Administered as two intramuscular doses 21 days apart, it elicits both humoral and cellular immunity, with peak antibody responses two weeks post-second dose.
In rhesus macaques given a clinical dose of NVX-CoV2373, plasma spike protein was about 100–300 fg/mL on day 1, roughly 10- to 333-fold below the 10^{3}–10^{5} fg/mL range reported after mRNA vaccination with the same assay; this is a single early time point in nonhuman primates rather than a human area-under-the-curve of antigen exposure. A planned human trial of circulating vaccine-derived spike protein was released by the FDA in August 2026 for operational and feasibility reasons and replaced with nonclinical biodistribution work.
A 2025 study validated an assay for detecting mucosal anti-SARS-CoV-2 spike IgA in saliva and reported significant increases following a booster dose of updated Novavax vaccines in previously mRNA-vaccinated participants; the study notes that, unlike repeated mRNA doses which show limited additional mucosal IgA boosting, this single Novavax booster elicited a modest response—though data on repeated Novavax doses is lacking—with modest seroresponse rates (7–13% for >3-fold increase) and cross-reactivity to variants including JN.1.
Phase 3 trials, including the PREVENT-19 study (NCT04611802) conducted in the United States and Mexico from December 2020 to May 2021, demonstrated 90.4% efficacy against symptomatic COVID-19 in adolescents aged 12-17 and 89.7% overall efficacy in adults against infection, primarily during circulation of pre-Delta variants. A UK trial reported 96.4% efficacy against the original strain and Alpha variant, with 100% protection against hospitalization and death. Efficacy waned against later variants like Omicron, but post-hoc analyses showed sustained protection against severe outcomes, including 100% against hospitalization in some cohorts through six months.
A 2025 retrospective cohort study in South Korean adolescents aged 12–18 reported adjusted hazard ratios for medically attended COVID-19 of 0.57 (95% CI: 0.31–1.05) for the primary series and 0.68 (95% CI: 0.54–0.84) for the third dose of NVX-CoV2373 versus BNT162b2, indicating a non-significant trend toward greater effectiveness after primary vaccination and significantly greater protection after boosting during Omicron dominance. A 2025 real-world study in South Korea compared NVX-CoV2373 to BNT162b2 after third and fourth doses using propensity score-matched groups from over 900,000 NVX doses and 1.2 million BNT doses administered February to December 2022, reporting adjusted hazard ratios for any SARS-CoV-2 infection of 0.78 (95% CI: 0.76-0.79) after the third dose and 0.86 (95% CI: 0.86-0.87) after the fourth, and for severe cases (ICU admission or death) of 0.73 (95% CI: 0.53-1.00) after the third and 1.21 (95% CI: 1.03-1.42) after the fourth.
Booster doses restored immunogenicity, with four sequential doses maintaining robust responses against ancestral and variant strains; a 2024 analysis of trial sera showed that up to four NVX-CoV2373 doses sustained IgG3 proportions and Fc effector functions (including ADCP, ADCC, and ADCD), without notable IgG4 class switching, in contrast to repeated mRNA vaccinations which increased Spike-specific IgG4—limited to mRNA vaccine recipients and those primed with mRNA vaccines, negatively correlated with neutralizing antibody levels and Fc effector functions, with in vitro evidence that increasing anti-S IgG4 lowered Fc effector functions—and reduced certain effector activities; boosting with adjuvanted protein-based Novavax XBB.1.5 partially overcame this anti-S IgG4 and Fc effector function immune imprinting. Additionally, in the booster setting, the protein subunit vaccine NVX-CoV2373 exerted a distinct and favorable effect on gut microbiome diversity, increasing alpha diversity in contrast to the patterns observed with mRNA and adenoviral vector booster vaccines.00053-7/fulltext)
One-year follow-up studies in Japanese adults confirmed persistent antibody responses up to one year post-primary series and after first and second boosters, alongside a well-tolerated safety profile. Real-world data from Italian studies during 2022–2023 showed effectiveness comparable to mRNA vaccines against symptomatic infection (~50–55% in early post-vaccination periods).
Safety profiles from trials indicated mostly mild to moderate reactogenicity, including injection-site pain, fatigue, and headache, resolving within days; severe events were rare and balanced with placebo.
The Booster Epidemiological Evaluation of Health, Illness, and Vaccine Efficacy (BEEHIVE) study (ClinicalTrials.gov NCT06065176) was a U.S. double-blind randomized trial comparing 2023–2024 (XBB.1.5) Novavax protein-subunit vaccine with Pfizer-BioNTech mRNA vaccine over 24 weeks (November 2023–August 2024). An Open Forum Infectious Diseases 2026 abstract reported reactogenicity results for 901 participants who completed at least one post-vaccination questionnaire (Novavax n=448; mRNA n=453); all had previously received at least two mRNA COVID-19 vaccine doses.
On day 1 after vaccination, 62.1% of Novavax recipients reported any solicited systemic reactogenicity event versus 75.8% of mRNA recipients (p<0.05); mean symptom counts were 1.4 versus 2.2. At least one Grade 2 or higher symptom occurred in 15.7% of Novavax recipients versus 33.6% of mRNA recipients, and Novavax recipients had an absolute 11.7 percentage-point lower rate of solicited local reactogenicity events. Events were transient, with no difference reported at day 6.
No vaccine-related deaths or anaphylaxis were linked to NVX-CoV2373 in primary analyses, though monitoring continues for rare events like myocarditis, which occurred at lower rates than with mRNA vaccines in comparative data. Long-term follow-up confirmed durability without emerging safety signals.
Licensure and access
The vaccine received Emergency Use Authorization in the United States in July 2022 for adults, extended to adolescents, and achieved full Biologics License Application approval on May 16, 2025, followed by approval of the 2025-2026 updated formula on August 27, 2025, with an extended shelf life of 6 months, positioning it as the sole non-mRNA option available domestically. Nuvaxovid received conditional marketing authorization from the EMA on December 20, 2021, followed by full marketing authorization in the European Union in 2022, with implementation in Italy via AIFA; first doses arrived in Italy in late February 2022, offered as a protein-based non-mRNA alternative for adults 18+ (later expanded to 12+), though uptake was relatively low compared to mRNA vaccines, with early reports indicating fewer than 16,000 doses administered in the initial weeks and overall niche adoption. Updated versions approved EU-wide include the XBB.1.5-adapted vaccine which became available in Italy in December 2023 with doses distributed by the Ministry of Health across regions for the seasonal campaign, and the JN.1-adapted 2024–2025 formula authorized by EMA in October 2024 maintaining access in Italy; the marketing authorization was transferred to Sanofi in 2025. In Germany, the updated JN.1 formula was made available on a limited basis starting in November 2025, rather than through broad public vaccination programs, with a shelf life of 9 months for unopened vials stored at 2-8°C for this variant, following a 2023 EMA extension from the original 9 months to 12 months for earlier versions, and endorsements from the World Health Organization for global use. Overall vaccination coverage for boosters remained modest, e.g., ~10.7% in the 2023–2024 autumn-winter campaign for those aged ≥60 in Italy, with Novavax contributing ~2.2% of doses EU-wide in that season. Over 5 million doses of NVX-CoV2373 have been administered globally. On April 9, 2026, Sanofi announced it had become the market authorization holder in Canada for Nuvaxovid following transfer from Novavax under their May 2024 collaboration, and said it would make Nuvaxovid available for the fall 2026–2027 season subject to provincial and territorial assessments. Ontario’s Ministry of Health 2026/2027 COVID-19 vaccine program lists Nuvaxovid (Sanofi Vaccines Canada; protein subunit; XFG-adapted; ages 12+) among publicly funded options alongside Spikevax and Comirnaty.
On 21 April 2026 Sanofi was selected to supply Sweden’s 2027/2028 national COVID-19 vaccination campaign with the protein-based Nuvaxovid vaccine, making Sweden the first country to procure exclusively a protein-based COVID-19 vaccine for a seasonal campaign.
In Austria, via the partnership with Sanofi since late 2025, access remains more restricted and niche-focused. It is primarily offered through select local health services, such as Impfservice Wien in Vienna, administered to individuals with contraindications to mRNA vaccines, age-specific needs from 12 years, or preferences for non-mRNA options. Appointments are required, and it is not widely stocked in general practitioners or pharmacies nationwide. Stock for the JN.1 variant became available in late 2025, with availability often patchy and prioritized for high-risk or mRNA-intolerant individuals.
Manufacturing scaled via partnerships, including U.S. government funding for 100 million doses, but early delays in production consistency and variant adaptation hindered initial distribution, contributing to lower uptake compared to mRNA platforms amid prioritized procurement of faster-to-deploy alternatives. Despite empirical evidence of efficacy, real-world adoption remained limited, partly due to timing and preferences for established options.
Influenza and Combination Vaccines
Novavax's stand-alone seasonal influenza vaccine candidate, based on its recombinant trivalent nanoparticle platform with Matrix-M adjuvant, builds on earlier NanoFlu development, where a prior Phase 3 trial achieved all primary immunogenicity endpoints against matched strains. The candidate targets hemagglutinin antigens from influenza A and B strains recommended annually by health authorities. In parallel, Novavax is advancing a COVID-19-influenza combination vaccine (CIC) that incorporates its NVX-CoV2373 spike protein nanoparticle with the trivalent influenza components, aiming to provide protection against both viruses in a single dose. On August 25, 2026, the U.S. Patent and Trademark Office issued U.S. Patent 12,714,744 B2 (application 17/736,452), assigned to Novavax, Inc., titled "Coronavirus and influenza compositions and methods for using them." The patent covers immunogenic compositions comprising a coronavirus S glycoprotein as a detergent-core nanoparticle with a non-ionic detergent, at least three hemagglutinin glycoproteins from different influenza strains, a pharmaceutically acceptable buffer, and optionally a saponin adjuvant (including Matrix-M–type Fraction A and Fraction C ISCOM matrices).
On December 9–10, 2024, Novavax initiated a Phase 3 trial (NCT06291857, CIC-E-301) of its COVID-19-influenza combination (CIC) and stand-alone trivalent nanoparticle influenza (tNIV) candidates in adults aged 65 and older, compared with Nuvaxovid and Fluzone High-Dose in a randomized, observer-blinded design. The trial enrolled 9,320 participants and was completed in February 2026. An initial cohort of approximately 2,000 participants provided descriptive immunogenicity data via hemagglutination inhibition and neutralizing-antibody assays.
Results from the initial cohort of about 2,000 participants, announced June 11, 2025, showed immune responses similar to the licensed comparators (2.4–5.7-fold rises over baseline). That cohort was descriptive and not adequately powered to demonstrate statistical significance. The CIC also elicited COVID-19 responses comparable to standalone NVX-CoV2373, with most solicited reactogenicity events (e.g., injection-site pain, fatigue) mild to moderate and resolving within days; no vaccine-related serious adverse events were reported in the cohort. A peer-reviewed abstract of the initial cohort, presented at IDWeek 2025 and published in Open Forum Infectious Diseases in January 2026, reported that 1,985 participants in Australia and New Zealand received a single dose of CIC, NVX-CoV2705 (Novavax's 2024-2025 JN.1 vaccine), tNIV or Fluzone High-Dose in a 3:2:1:3 ratio. Solicited local and systemic reactions within 7 days were reported more often after CIC (66.7% and 42.3%) and tNIV (64.8% and 44.0%) than after NVX-CoV2705 (36.4% and 31.5%) or Fluzone High-Dose (48.7% and 36.2%); most events were Grade 1, with about 1% Grade 3. Unsolicited adverse events through Day 28, including serious adverse events (0.5% to 1.4%), occurred at similar frequencies across groups, and no myocarditis, pericarditis or deaths were reported. All authors were Novavax employees and shareholders.
The FDA placed the IND on clinical hold on October 16, 2024, after a spontaneous report of a serious adverse event in a 2023 Phase 2 participant (initially reported as motor neuropathy and later reclassified as ALS, judged not related to vaccination); the hold was lifted on November 11, 2024. A separate lot-consistency study (NCT06482359) was withdrawn before enrolling anyone. In May 2024, Novavax partnered with Sanofi under a co-exclusive license, granting Sanofi rights to develop and commercialize certain influenza and COVID-influenza combinations (including integration with Sanofi's Flublok), with Novavax eligible for up to $1.2 billion in milestones and royalties; however, Novavax retained flexibility to pursue its proprietary nanoparticle-based CIC independently.
Other Pipeline Candidates
Novavax maintains a portfolio of early-stage vaccine candidates beyond its primary focus on COVID-19 and influenza programs, leveraging its recombinant nanoparticle platform and Matrix-M adjuvant. These efforts target respiratory and bacterial diseases, though most remain in preclinical development as of 2025.
In preclinical stages, Novavax is developing combination vaccines incorporating respiratory syncytial virus (RSV) antigens, potentially paired with human metapneumovirus (hMPV) or other respiratory pathogens, utilizing nanoparticle protein constructs adjuvanted with Matrix-M to elicit broad immune responses. This approach aims to address unmet needs in pediatric and adult populations vulnerable to RSV-related lower respiratory tract infections. Novavax is also advancing a preclinical avian influenza A(H5N1) vaccine candidate using recombinant full-length hemagglutinin (HA) from the A(H5N1) clade 2.3.4.4b strain (A/American Wigeon/SC/2021) combined with Matrix-M adjuvant to form nanoparticles (H5-MNP). In naïve mice, two doses (intramuscular or intranasal) elicited strong neutralizing antibodies, hemagglutination inhibition titers, Th1 CD4+ T-cell responses, and mucosal IgA in lungs via the intranasal route. In non-human primates primed with seasonal influenza vaccine, one intramuscular dose achieved 100% seroconversion with high neutralizing antibodies, while two intranasal doses provided comparable protection, boosting Th1 T-cells and antibodies targeting conserved HA epitopes including the head receptor-binding site, VE subdomain, and stem. These findings suggest potential for single-dose protection in humans with prior seasonal flu immunity, broad coverage against drifted strains, and rapid pandemic response including needle-free intranasal administration.
Additional preclinical candidates include a vaccine against varicella-zoster virus for shingles prevention, focusing on glycoprotein nanoparticle formulations to induce durable T-cell and antibody responses in older adults, and a Clostridioides difficile (C. diff) vaccine program. On 9 September 2026 at the 9th International C. Difficile Symposium, Novavax presented preclinical data on three Matrix-M–adjuvanted constructs—Q-Tox, P-Tox and C-Tox—with P-Tox as the current lead. In a hamster lethal challenge with hypervirulent NAP1 spores, 75% (6/8) of P-Tox–immunized animals survived versus 25% (2/8) on a toxoid comparator; in a mouse toxin B challenge, 100% (10/10) survived at a 3 μg P-Tox dose versus 80% (8/10) on a 10 μg toxoid comparator. The company stated it remains on track to advance the program into clinical development as early as 2027. There are currently no FDA-approved vaccines for prevention of C. difficile infection.
Partnerships and Collaborations
Licensing Agreements and Partnerships
Novavax's licensing agreements and partnerships have primarily focused on enabling the manufacture, supply, and commercialization of its protein nanoparticle vaccines and Matrix-M adjuvant, compensating for the company's constrained internal production capabilities during the COVID-19 pandemic and beyond. These collaborations, often involving upfront payments, milestones, and royalties, have provided critical revenue streams and global reach, with partners handling regional regulatory approvals and distribution.
Manufacturing and Regional Partnerships
In February 2021, Novavax entered a collaboration and exclusive license agreement with the Serum Institute of India (SII), granting SII rights to manufacture the NVX-CoV2373 COVID-19 vaccine antigen for commercialization in up to 110 low- and middle-income countries, while Novavax supplied the Matrix-M adjuvant. SII markets the product as Covovax, which has generated ongoing royalties for Novavax, and the partnership extended to supplying Matrix-M for the R21/Matrix-M malaria vaccine, developed in partnership with SII and Oxford University, which has sold 25 million doses since its launch in mid-2024, achieving 85% market share in the growing market via partners as reported by Novavax in its presentation at the 44th Annual J.P. Morgan Healthcare Conference in January 2026. In November 2025, Gavi and UNICEF announced an equitable pricing agreement reducing the price of the R21/Matrix-M vaccine to US$2.99 per dose, yielding savings of up to US$90 million and enabling procurement of over 30 million additional doses to protect nearly 7 million more children by 2030, further enhancing accessibility in malaria-endemic regions. This reflects continued progress in addressing urgent and unmet needs in malaria-endemic regions. This deal facilitated over 100 million doses produced by SII by mid-2022, addressing supply gaps in developing markets. In May and August 2022, Novavax expanded its license and supply arrangements with SII to cover its proprietary COVID-19 variant antigen candidates, its quadrivalent influenza vaccine candidate and its COVID-Influenza Combination (CIC) vaccine candidate, so that SII could manufacture and commercialize a vaccine targeting COVID-19 variants including Omicron subvariants, a quadrivalent influenza vaccine and a CIC vaccine, and supply such vaccines to Novavax, according to Novavax's Form 10-Q for the quarter ended 30 September 2022; its preceding quarterly report had described the expansion only for the variant antigen candidates.
Novavax signed a similar collaboration and license agreement with SK Bioscience in South Korea in July 2021, providing exclusive rights for SK to develop, manufacture, and commercialize the COVID-19 vaccine domestically, with expansions in December 2021 for additional antigen production capacity. In July 2022, the European Medicines Agency approved a variation to the marketing authorization for Nuvaxovid, authorizing SK Bioscience to manufacture and supply the active substance (drug substance/antigen) for supply to the EU, building on SK's existing production role and its facility's EU-GMP certification; SK primarily handles drug substance production, while final formulation and fill-finish may involve other partners, as part of the ongoing conditional marketing authorization that includes updated variants such as the 2024-2025 formula. That same month, the agreement expanded further for Omicron-adapted variants in prefilled syringes. In August 2023, SK acquired a 7% equity stake in Novavax for $85 million to deepen the strategic alliance amid endemic transition, and the partnership further expanded in July 2025 to supply 40 million doses for South Korea.
Novavax established a manufacturing partnership with Mabion S.A., a Polish biotechnology company and CDMO based in Konstantynów Łódzki, through a Master Service Agreement signed in March 2021 (with planning from late 2020) for technology transfer and GMP-compliant production of the recombinant spike protein antigen using Sf9 insect cell lines from Spodoptera frugiperda for the NVX-CoV2373 COVID-19 vaccine (branded Nuvaxovid in the EU). This was followed by an initial commercial agreement in October 2021 valued at up to $372 million, covering production through 2025 with extensions to 2026, expansions for variants including Omicron and XBB.1.5, analytical services, quality control, logistics, and support for COVID-influenza combination candidates using large-scale bioreactors up to 2,500L. Achievements include technology transfer completed in approximately 30 weeks, a 100% batch success rate and schedule adherence per Novavax KPIs, with production starting in 2022 and contributing to EU supply under the conditional marketing authorization.
For Japan, Novavax granted Takeda Pharmaceutical an exclusive license in May 2021 to develop, manufacture, and commercialize Nuvaxovid, with terms improved in May 2025 to enhance milestone structures and royalties following regulatory approval in September 2025, which triggered an undisclosed payment. Takeda has since marketed the vaccine, contributing royalties tied to net sales during the 2025-2026 season.
Major Strategic Alliances
The most substantial recent partnership materialized on May 10, 2024, with Sanofi, under a co-exclusive license agreement valued at up to $1.2 billion, including a $500 million upfront payment to Novavax and a minority equity investment of less than 5%, for co-commercializing the standalone COVID-19 vaccine globally (excluding certain regions) and developing a COVID-influenza combination vaccine, with Sanofi receiving a sole license for the combo product containing its flu vaccine strains and being solely responsible for its development and commercialization. On 5 October 2026, the EU Clinical Trials Information System authorised a Phase 3 study of that combination (EUCT 2026-526221-18-00, protocol VBT00004), sponsored by Sanofi Vaccines US Inc. of Swiftwater, Pennsylvania; the trial is authorised with recruitment pending, plans 8,015 adults aged 60 years and older, and lists EU/EEA sites in Germany, Belgium, and Portugal. It plans 3,215 participants in the EU (Germany 2,050, Belgium 685, Portugal 480) and 4,800 elsewhere (Costa Rica, Mexico, Colombia, Panama, Honduras and the United Kingdom). The primary endpoints are antibody titres against each of the three influenza strains and the SARS-CoV-2 variant. The test product is Fluzone High-Dose admixed with baculovirus-expressed, Matrix-M–adjuvanted SARS-CoV-2 spike antigen (NVX-CoV2373); comparators include Nuvaxovid, for which Sanofi Winthrop Industrie is the marketing-authorisation holder, and Efluelda. Starting in 2025, Sanofi will book sales of the adjuvanted COVID-19 vaccine and support certain R&D, regulatory, and commercial expenses, while Novavax receives tiered double-digit percentage royalties on Sanofi's sales of COVID-19 vaccines and COVID-19-influenza combination vaccines, plus up to $700 million in development, regulatory, and launch milestones. Under the agreement, Novavax is eligible for a $125 million milestone when a Sanofi CIC Phase 3 trial starts in the U.S. or EU, plus a $225 million CIC launch milestone and royalties in the high teens to low twenties percent on CIC sales. A separate $75 million milestone is tied to finishing the transfer of Nuvaxovid manufacturing technology to Sanofi, which is expected in mid-2027. Outside the collaboration, each party may independently develop and commercialize their own COVID-19-influenza combination vaccines and adjuvanted products at their own cost. Sanofi also holds a non-exclusive license for Matrix-M in other indications, entitling Novavax to development, launch, and sales milestone payments of up to $200 million for each of the first four Adjuvant Products and $210 million for each Adjuvant Product thereafter, and mid-single digit sales royalties for 20 years on Sanofi’s sales of all such licensed products. The deal progressed with $25 million milestones in October 2025 upon transferring Nuvaxovid's EU marketing authorization to Sanofi and on November 4, 2025, following completion of the U.S. marketing authorization transfer for Nuvaxovid, with Sanofi assuming responsibility for U.S. commercialization, and was amended on September 30, 2025, to expand Sanofi's Matrix-M access for its pandemic influenza programs; Sanofi received funding from the Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response of the U.S. Department of Health and Human Services, under Contract 75A50122D00003 for early-stage work on this vaccine candidate including the Matrix-M adjuvant. In its 6 August 2026 second-quarter results, Novavax stated that Sanofi had received Fast Track designation from the U.S. Food and Drug Administration for Sanofi's H5 pandemic influenza vaccine candidate (SP0335) utilizing Matrix-M. Sanofi's Phase 1/2 study NCT07779408 evaluates egg-based H5N8 influenza vaccine formulations at multiple dose levels with and without Matrix-M adjuvant in healthy adults aged 18 and older in the United States. This alliance integrates Novavax's adjuvant into Sanofi's broader portfolio. On 28 August 2026 Novavax announced that partners had received approvals for an XFG-adapted Nuvaxovid formulation for the 2026–2027 vaccination season in the United States, European Union and Japan. Under the Sanofi collaboration, Sanofi leads commercialization in most major markets; Takeda commercializes the vaccine in Japan. Novavax remains eligible for royalties on partner net sales and regulatory/seasonal milestones without operating its own commercial infrastructure for the product.
On January 15, 2026 (the effective date), Novavax entered into a License and Option Agreement with Pfizer, providing a non-exclusive, worldwide license to the Matrix-M adjuvant technology for Pfizer to research, develop, and commercialize in vaccine products for at least one and up to two infectious disease fields, with the first field already selected and the second field to be chosen at Pfizer's option subject to certain limitations. The License and Option Agreement provides Pfizer the opportunity to license the Matrix-M technology in a Second Field that has not yet been specified but that Pfizer may designate at any time during the term. The Second Field may pertain to any infectious disease, so long as Novavax does not already have a relevant IND filed or has previously granted an exclusive license or similar right pertaining to such infectious disease that would preclude such grant. Under the agreement, Pfizer has control over all matters relating to the development, manufacture, and commercialization of products containing the adjuvant, apart from the delivery and supply of the adjuvant as detailed in contemplated supply agreements. Novavax received an upfront payment of $30 million and is eligible for up to $500 million in development and sales milestones, plus tiered high mid-single digit percentage royalty payments on sales of any Pfizer product including Matrix-M. Pfizer is solely responsible for the development and commercialization of its products utilizing Matrix-M, while Novavax is responsible for the supply of Matrix-M.
Adjuvant Research Collaborations
In June 2023, Novavax entered a three-year agreement with the Bill & Melinda Gates Medical Research Institute to supply Matrix-M adjuvant for preclinical vaccine research against diseases such as malaria and tuberculosis.
Novavax has signed material transfer agreements (MTAs) for its Matrix-M adjuvant with two top 10 pharmaceutical companies beyond its current partners, one additional large pharmaceutical company, and an oncology company, as stated by CEO John Jacobs at the 44th Annual J.P. Morgan Healthcare Conference, as part of efforts to expand partnerships.
Network Efforts by Novavax and Its Partners
On 29 April 2026 a roundtable discussion was held at the French residence in Stockholm, convened by Business France, Nordic Infucare and Sanofi, aimed at securing France’s and Sweden’s roles as a European hub for medical innovation, including retention of research, development and manufacturing. The roundtable release did not name Novavax; the connection is through Sanofi’s commercialization of Nuvaxovid and Novavax AB’s continued manufacture of the Matrix-M adjuvant at its Uppsala plant.
On 8 September 2026 Novavax Managing Director Åsa Manelius took part in a 30-minute Expo Stage panel at Nordic Life Science Days in Stockholm, hosted by Stockholm-Uppsala. The session, titled “Where Science Meets Scale: Novavax, AstraZeneca, Pelago Bioscience, Orexo and the Power of the Stockholm-Uppsala Life Science Cluster,” examined how the region’s science, talent, entrepreneurship and ecosystem can confer a global competitive advantage.
On 20 October 2026 Robert Walker, Executive Vice President and Head of Research and Development at Novavax, is listed on the opening keynote panel “The Technology Revolution: Agility for the Wave of Next Generation Vaccines” at the World Vaccine Congress Europe in Amsterdam, with Annaliesa Anderson of Pfizer, Saranya Sridhar of Sanofi, moderator Peter Marks of Eli Lilly, and Marco Cavaleri, Charlotte Vernhes, Jerome Kim and Lucy Chappell.
Financial and Operational Performance
Funding Sources and Revenue Streams
Novavax has historically relied on a combination of grants from philanthropic organizations and government contracts to fund its research and development efforts. In 2015, the company received a grant of up to $89 million from the Bill & Melinda Gates Foundation to support development of its RSV F vaccine, including a Phase 3 clinical trial for maternal immunization to protect infants. These non-dilutive funds were critical for a pre-revenue biotech firm, enabling progression of candidates like its respiratory syncytial virus vaccine without immediate commercial pressures.
The company's funding landscape shifted dramatically during the COVID-19 pandemic, with substantial U.S. government support under Operation Warp Speed. In July 2020, Novavax secured $1.6 billion from the U.S. Department of Health and Human Services and Department of Defense to accelerate development, manufacturing, and delivery of up to 100 million doses of its NVX-CoV2373 vaccine candidate by early 2021. Similarly, in August 2021, Novavax finalized an advance purchase agreement with the European Commission for up to 100 million doses of NVX-CoV2373, with an option for an additional 100 million doses through 2023, totaling a potential 200 million doses, as part of the EU's strategy to secure diverse vaccine options during the pandemic. However, in August 2021, the U.S. government paused further funding for vaccine production due to quality control issues at a subcontractor manufacturing facility, though this did not affect funding for clinical trials. Additional grants included up to $384 million from the Coalition for Epidemic Preparedness Innovations (CEPI) in May 2020 for Phase 1/2/3 trials and scale-up, and a $60 million Department of Defense contract in June 2020 for production support. These at-risk investments, totaling over $2 billion by late 2020, enabled rapid pivoting from preclinical stages to global trials but exposed the firm to repayment obligations if milestones were unmet, though no such clawbacks were reported post-authorization.
Revenue streams post-2020 have centered on product sales of its authorized COVID-19 vaccine, Nuvaxovid, alongside collaboration milestones and royalties from licensing deals. In 2024, Novavax reported $682 million in annual revenue, primarily from vaccine sales and government procurements, though this marked a 31% decline from 2023 amid waning demand. For 2025, the company projected adjusted total revenue of $975 million to $1.025 billion, including $300 million to $350 million from licensing, royalties, and other non-product sources, driven by reduced sales offset by partnership inflows. Third-quarter 2025 results reported $70 million in total revenue, including $225 million from Sanofi partnership milestones, and a $202 million net loss, with profitability now targeted for 2028.
Strategic partnerships have emerged as a key revenue diversifier, emphasizing out-licensing of its Matrix-M adjuvant and vaccine platforms to mitigate manufacturing risks. The May 2024 collaboration and license agreement with Sanofi, valued at up to $1.2 billion, includes $500 million upfront, potential milestones up to $700 million, and tiered royalties on sales; this generated $459 million in 2024 revenue recognition and a $25 million milestone in October 2025 upon transferring Nuvaxovid's EU marketing authorization. Earlier deals, such as with Serum Institute of India and SK bioscience, provide royalties on commercialized doses in respective territories, contributing to "other partners" revenue categories reported quarterly. Through its partnership with Takeda, Novavax achieved over 12% market share for Nuvaxovid in Japan in 2025. These arrangements shift Novavax toward a leaner model, prioritizing adjuvant licensing over direct vaccine commercialization, though execution depends on partner advancements in influenza and combination products.
In August 2025, Novavax completed a refinancing of its convertible debt, issuing $225 million in aggregate principal amount of 4.625% Convertible Senior Notes due 2031, consisting of approximately $175.3 million exchanged for about $148.7 million principal of existing 5.00% Convertible Senior Notes due 2027 (leaving ~$26.5 million outstanding) and $49.7 million raised in cash via new issuances. This extended maturities, reduced the interest rate, and enhanced liquidity amid ongoing cash burn. Prior to the August 2025 refinancing, the 2027 convertible notes (CUSIP 670002AD6) were held by various institutional investors, primarily hedge funds specializing in convertible arbitrage and multi-strategy approaches, as disclosed in public SEC 13F filings. Notable reporting holders included Context Capital Management, LLC (a dedicated convertible bond specialist, with positions of approximately $19–20 million principal in 2024–2025 quarters), Point72 Asset Management, L.P. (multi-strategy, reporting ~$4–13 million principal across periods), and Skaana Management L.P. (convertible arbitrage focus). Aggregated 13F data from sources directly linked to EDGAR filings confirm an active convertible investor ecosystem around the notes. Company filings state the exchanges were privately negotiated with unnamed holders, and no specific participation in the 2031 notes rollout was disclosed.
In February 2026, Novavax entered into a Credit, Security and Guaranty Agreement with MidCap Financial Trust, establishing a senior secured term loan facility of up to $330 million available in four tranches. On February 25, 2026, the company drew the initial $50 million from Tranche 1. The facility carries interest at Term SOFR + 5.00% (2% floor), matures March 1, 2031 (interest-only), and is secured by a first-priority lien on substantially all assets. It includes a minimum $100 million unrestricted cash covenant and additional royalty-revenue tests for later draws.
Key Financial Milestones and Challenges
Novavax faced persistent financial difficulties prior to the COVID-19 pandemic, characterized by annual net losses exceeding $100 million for much of the 2010s, low revenue from limited product sales and grants, and reliance on dilutive equity offerings and government contracts to fund operations. For instance, following the failure of the Resolve Phase 3 trial for its RSV vaccine in September 2016, the company's stock price dropped approximately 85%. After the ResVax Phase 3 trial failure in February 2019, shares fell nearly 70%. To avoid Nasdaq delisting, Novavax implemented a one-for-twenty reverse stock split in May 2019. For instance, revenue in the first quarter of 2020 was just $3.4 million, reflecting a 15% year-over-year decline driven by reduced collaboration income.
A pivotal milestone occurred on July 7, 2020, when Novavax secured $1.6 billion in funding from the U.S. government's Operation Warp Speed program to accelerate development and manufacturing of its COVID-19 vaccine candidate, NVX-CoV2373, marking the largest such award to date and enabling Phase 3 trials. This infusion catalyzed revenue growth, with full-year 2021 revenue reaching $1.15 billion, followed by a peak of $1.98 billion in 2022, primarily from vaccine sales and related agreements.
Post-pandemic demand contraction posed severe challenges, with revenue falling to $984 million in 2023 and $682 million in 2024 amid manufacturing delays, regulatory hurdles, and reduced global orders, leading to net losses of $545 million in 2023 despite cost-cutting efforts. In February 2023, the company issued a going-concern warning, citing insufficient cash to sustain operations beyond early 2024 without additional financing, which triggered a 25% stock plunge.
Recent milestones include a May 2024 partnership with Sanofi, yielding upfront payments and milestones such as a $50 million trigger in December 2024 for database lock and a $25 million payment in October 2025 upon transfer of EU marketing authorization for Nuvaxovid. In August 2025, Novavax reported second-quarter results showing a surprise profit, with $239 million in revenue and GAAP EPS of $0.62, primarily driven by milestone payments from the Sanofi partnership. Additionally, the company completed a convertible debt refinancing, issuing $225 million in aggregate principal amount of 4.625% Convertible Senior Notes due 2031 through privately negotiated exchanges and subscriptions; this exchanged approximately $175 million of the new notes for existing 5.00% Convertible Senior Notes due 2027, leaving about $26.5 million outstanding, while raising additional cash, extending maturities from 2027 to 2031, reducing the interest rate from 5.00%, and improving liquidity terms. In October 2024, the U.S. FDA placed a clinical hold on Novavax's investigational new drug applications for its COVID-19-influenza combination and stand-alone influenza vaccine candidates due to a reported case of motor neuropathy, causing shares to drop as much as 24% intraday—the largest since July—though the hold was lifted on November 11, 2024, after review found no causal link. In November 2024, Novavax entered into a settlement agreement with the Secretary of State for Business, Energy and Industrial Strategy (assigned to the UK Health Security Agency), acting on behalf of the government of the United Kingdom (the "Authority"), terminating the Amended and Restated Supply Agreement and settling a dispute over upfront payments of $112.5 million. Novavax agreed to refund $123.8 million, including $11.3 million in interest, in equal quarterly installments of $10.3 million over three years, ending June 2027. As of September 30, 2025, the remaining amount was classified as $38.0 million in other current liabilities and $30.0 million in other non-current liabilities on its consolidated balance sheet. However, ongoing challenges persist, including projected long-term losses through 2027, a 31% annual revenue decline forecast to 2028, and aggressive restructuring like site consolidations expected to yield $60 million in asset sales by early 2026 while cutting R&D and SG&A expenses by 85% from 2022 levels by 2027.
On 6 August 2026, Novavax reported second-quarter 2026 total revenue of $57 million, compared with $239 million in the second quarter of 2025, when results included $202 million from a $175 million milestone for U.S. Biologics License Application approval of Nuvaxovid and a $27 million Takeda amendment. Product sales were $19 million, 76% higher than a year earlier, which the company attributed to higher Matrix-M adjuvant demand and sales to license partners. Net loss was $53 million, compared with net income of $107 million in the second quarter of 2025. Cash, cash equivalents, marketable securities and restricted cash totaled $724 million as of 30 June 2026, compared with $751 million at 31 December 2025. The company raised its full-year 2026 Adjusted Total Revenue framework to between $235 million and $275 million and lowered Combined R&D and SG&A expense guidance to $370–$410 million from $380–$420 million as of 6 May 2026. On 5 November 2026, Novavax reported third-quarter 2026 total revenue of $68 million, compared with $70 million in the third quarter of 2025; product sales were $26 million; net loss was $31 million, compared with a net loss of $202 million a year earlier; cash, cash equivalents, marketable securities and restricted cash were $627 million as of 30 September 2026; and the company raised its full-year 2026 Non-GAAP Adjusted Total Revenue framework to between $385 million and $415 million while updating Combined R&D and SG&A expense guidance to $375–$395 million.
| Year | Revenue (USD millions) | Net Loss (USD millions) |
|---|---|---|
| 2021 | 1,150 | -670 |
| 2022 | 1,980 | -658 |
| 2023 | 984 | -545 |
| 2024 | 682 | -188 |
Shareholder Structure
After the one-for-twenty reverse stock split effective 10 May 2019, Novavax had approximately 23 million shares outstanding. The company thereafter issued additional shares through at-the-market (ATM) programs, underwritten offerings and private placements. In 2020 ATM sales generated net proceeds of about $874 million, together with a $200 million convertible preferred placement later converted into common stock. Further ATM sales in 2023 (tens of millions of shares) and a private placement of 6.5 million shares to SK bioscience at $13 per share, among other issuances, expanded the share count to roughly 78 million at year-end 2022, 101 million at year-end 2023, 152 million at year-end 2024 and 162.9 million as of 16 February 2026 (164.9 million as of 31 July 2026).
Shah Capital Management began purchasing shares in late 2022, reporting 715,000 shares at 31 December 2022. It filed a Schedule 13D on 27 April 2023 disclosing a 5.28 % stake (4.55 million shares) and subsequently increased its holding to more than 14 million shares (approximately 8.6–9.1 %) by 2026, becoming one of the largest shareholders.
As of 2026 SEC 13F and 13D/G filings, institutions held a majority of the shares (approximately 59 percent), while retail investors comprising the general public held approximately 28 percent. The largest reported holders included The Vanguard Group (approximately 9.4 %, 15.5 million shares), Shah Capital Management (approximately 8.6 %, 14.2 million shares), BlackRock (approximately 8.5 %, 13.9 million shares), State Street (approximately 7.1 %, 11.7 million shares) and Sanofi (approximately 4.2 %, 6.88 million shares). Retail investors have held shares since the May 2019 reverse split and purchased shares issued via at-the-market programs during the 2020–2021 rally that BioSpace compared to GameStop's gains, as the stock rose from a few dollars at year-end 2019 to a high of $319.93 in February 2021, including 1.7 million shares sold for $452 million in net proceeds from 22 January to 24 February 2021. They remained holders through the 92.8 percent decline in 2022. Sanofi acquired its minority stake of less than 5 % (reported as 4.9 % at issuance for $70 million) in May 2024 as part of the collaboration and license agreement. Insiders held under 1 % (approximately 1.2 million shares).
Recent Restructuring Efforts (2023–2025)
In May 2023, Novavax announced a global restructuring and cost reduction plan amid declining demand for its COVID-19 vaccine, which included laying off approximately 25% of its workforce, affecting hundreds of employees across research, development, and commercial operations. The initiative aimed to reduce annual research and commercial expenses by 20% to 25% from 2022 levels, targeting $1.3 billion to $1.4 billion in total spending for 2023 and further cuts of 40% to 50% by 2024, while prioritizing manufacturing efficiencies and pipeline focus on combination COVID-influenza vaccines.
By November 2023, the company reported partial success, with operating expenses decreased by $95 million for the first nine months compared to the prior year, and indicated plans for additional cuts to align costs with reduced vaccine revenues. In January 2024, Novavax executed a second round of layoffs impacting 12% of its global staff, primarily in administrative and research roles, as part of a broader cost-saving effort to bring combined R&D and selling, general, and administrative (SG&A) expenses below $750 million for the year. This included $300 million in reductions from general and R&D expenses, with full annual impacts expected in 2025 and one-time severance charges of $4 million to $7 million. Overall, these 2023–2024 measures resulted in a cumulative workforce reduction of about 30%, leaving approximately 952 full-time employees as of February 2025, alongside manufacturing optimizations and pipeline reprioritization to enhance financial sustainability.
In December 2024, Novavax sold its manufacturing facility in Bohumil, Czech Republic, to Novo Nordisk for $200 million, structured as $190 million in 2024 and $10 million in 2025. This divestiture reduced the company's manufacturing footprint, generated cash proceeds, and supported cost-saving initiatives by allowing focus on core vaccine development and operations.
In July 2025, Novavax implemented another significant restructuring, cutting 25% of its remaining workforce—approximately 500 positions, with 80% affecting full-time employees—to further streamline operations and reduce cash burn amid ongoing revenue challenges from low COVID-19 vaccine uptake. This followed delays in FDA approvals and clinical holds, positioning the company for a pivot toward commercializing approved products like its updated COVID-19 vaccine formulas and potential partnerships.
On October 22, 2025, Novavax announced that it had signed definitive agreements, dated October 17, 2025, with AstraZeneca Pharmaceuticals LP covering its former headquarters at 700 Quince Orchard Road in Gaithersburg, Maryland: an assignment of the lease for the roughly 171,000-square-foot facility (leased from an affiliate of Alexandria Real Estate Equities, with a term through December 2036) for a $15.0 million fee, the sale of about 9.7 acres of adjacent land for $20.0 million, and the sale of equipment, furniture and other on-site assets for $24.8 million, for an aggregate of $59.8 million payable by AstraZeneca—$20.0 million in the fourth quarter of 2025 and about $39.8 million in the first quarter of 2026, with the lease assignment to take effect on January 5, 2026. Novavax said the consolidation would save about $230 million in lease and facility operating costs over 11 years; it moved its corporate headquarters to 21 Firstfield Road, Gaithersburg, and expected a non-cash impairment charge of $96 million to $98 million in the third quarter of 2025. These actions, detailed in SEC filings, reflect a multi-year effort to adapt to post-pandemic market realities, with R&D spending on certain activities rising to $204 million in 2024 from $58.8 million in 2023 due to targeted investments despite overall cuts.
Public and Expert Reception
Early results from the UK phase 3 trial for NVX-CoV2373, demonstrating 89.3% efficacy against COVID-19, elicited positive commentary from Paul Heath, chief investigator of the UK phase 3 trial and professor of paediatric infectious diseases at St George’s University Hospitals NHS Foundation Trust, who said on 29 January 2021 that the findings were enormously exciting and “wonderful news.” Clive Dix, chair of the UK Vaccine Taskforce, called them “spectacular results” in Novavax’s 28 January 2021 release. The same night, Shabir Madhi, principal investigator of the South African phase 2b trial and dean of the Faculty of Health Sciences at the University of the Witwatersrand, told a briefing that 60% protection in people without HIV against the B.1.351 variant was “something I did not dream of,” that it “might sound disappointing,” and that the vaccine was then the only one showing objective efficacy against that variant; he also reported that prior infection with the prototype virus had not protected participants against B.1.351 illness. Madhi restated the South African findings in a 1 February 2021 article for The Conversation. Novavax's NVX-CoV2373 COVID-19 vaccine received generally favorable assessments from experts regarding its clinical efficacy and safety profile, with phase 3 trials demonstrating 90.4% efficacy against symptomatic infection and 100% protection against moderate and severe disease. Immunologists highlighted the vaccine's strong antibody responses, which exceeded those reported for other candidates in early data, attributing this to its recombinant protein nanoparticle platform combined with the Matrix-M adjuvant; the effectiveness of Matrix-M was further demonstrated in the independently developed R21 malaria vaccine, WHO-prequalified in 2023, which showed 68–75% efficacy against clinical malaria in phase 3 trials in African children. 02511-4/fulltext) Safety analyses across randomized controlled trials confirmed mostly mild-to-moderate reactogenicity, with no new safety signals beyond those seen in other COVID-19 vaccines, leading advisory bodies like the CDC's ACIP to recommend it for adults aged 18 and older under emergency use authorization.
However, expert commentary also critiqued operational shortcomings, particularly manufacturing inconsistencies that delayed regulatory submissions and global supply commitments, as evidenced by shortages in critical components like purification filters and assay validations. These issues, rather than flaws in the underlying science, were cited by regulators and analysts as primary barriers to broader adoption, with FDA delays in full approval extending into 2025 despite meeting efficacy thresholds. Some scientists noted that while NVX-CoV2373's protein-based approach offered advantages in stability and familiarity—resembling traditional vaccines like those for influenza—its real-world effectiveness as a booster appeared lower (around 55% against symptoms) compared to mRNA options in observational data.
Public reception was muted, marked by low uptake despite positioning as a non-mRNA alternative appealing to those skeptical of nucleic acid technologies. On 19 July 2022, CDC director Rochelle Walensky, accepting ACIP’s vote, told adults who had been waiting for “a COVID-19 vaccine built on a different technology than those previously available” that “now is the time to join the millions of Americans who have been vaccinated.” ACIP voting member Oliver Brooks said the primary target was the still-unvaccinated, with the hope that the protein-subunit vaccine would “change them over from being unvaccinated to being vaccinated.” By late 2022, fewer than 62,000 doses had been administered in the U.S. out of nearly one million delivered, reflecting broader vaccine fatigue and the vaccine's late entry amid dominant mRNA campaigns. Under the July 2022 emergency-use authorization the vaccine was supplied in 10-dose vials that had to be discarded six hours after first puncture. Provider guidance directed that an eligible person should still be vaccinated even if that required opening a vial for a single appointment, with unused doses recorded as waste.
This niche interest was amplified by dedicated online communities, such as "Novastans" on platforms like Reddit, fostering a following among mRNA vaccine skeptics as well as overlapping groups of retail investors who viewed potential approvals as a catalyst for the share price.
A subset of these retail investors has also advanced more detailed, forward-looking readings of Novavax’s post-COVID strategy, interpreting public disclosures on Matrix-M licensing (including the Sanofi combination program and a separate Pfizer license) and material-transfer agreements as evidence that the company is repositioning the adjuvant as a multi-indication platform asset.
On 4 November 2024 Novavax announced that Åsa Manelius would join in February 2025 as Managing Director of Novavax AB in Uppsala, the primary manufacturing site for Matrix-M, responsible for manufacturing and development of the matrix adjuvants. She spent five years at AstraZeneca in Södertälje, from December 2019 as General Manager, Sweden Biologics, the strategic launch and commercial drug-product supply site, and from July 2023 as Therapy Area Lead, Respiratory & Immunology, Global Supply Chain and Strategy. From 2010 to 2019 she was Managing Director and Site Lead at Biora AB; before that she was a member of the executive leadership team at Pfizer Health AB’s biologics manufacturing site in Sweden for more than ten years. Rick Crowley, then Chief Operations Officer, said the Uppsala site would supply Matrix-M for the pipeline and potential partners while the company drove value through partnerships and R&D. On 8 September 2026, at Nordic Life Science Days in Stockholm, the 30-minute Expo Stage session hosted by Stockholm-Uppsala was titled “Where Science Meets Scale: Novavax, AstraZeneca, Pelago Bioscience, Orexo and the Power of the Stockholm-Uppsala Life Science Cluster.”
In the 6 May 2026 release “Novavax Reports First Quarter 2026 Financial Results and Operational Highlights,” CEO John C. Jacobs reported four new Matrix-M material-transfer agreements: an April agreement with an unnamed top-ten company described as a global oncology leader, covering oncology targets, antibiotic-resistant bacterial infections, and other infectious diseases (described on that day’s earnings call as the third oncology-focused MTA and the first with a top-ten company); an April agreement giving an existing Matrix-M licensee access for up to nine further identified infectious-disease areas; a February expansion, by one field, of an existing material-transfer agreement with a major global pharmaceutical company; and a February agreement with a small oncology company. Jacobs described the nine-area agreement and the one-field expansion as deepenings of relationships with current licensees.
Beginning in early 2023, Don Ford began sustained advocacy promoting Novavax as a non-mRNA option for long-COVID patients and vaccine-hesitant groups, evolving into Organizing for a Better Tomorrow (OFABT), led by Ford (online as @DonEford and host of the Brace for Impact show), which delivered repeated public testimonies at FDA VRBPAC meetings (starting June 15, 2023, with further presentations in 2024 and May 22, 2025), ran petitions for pediatric use and earlier approvals, hosted Brace for Impact strategy sessions, and in April 2025 mobilized over 3,200 public comments and calls to the FDA and ACIP during BLA delays.
Ford’s and OFABT’s advocacy is rooted in platform-specific immunological distinctions drawn from peer-reviewed studies. Ford has cited evidence that repeated mRNA vaccination is associated with an increase in spike-specific IgG4 antibodies (a shift not observed with Novavax’s recombinant protein formulation; Kalkeri et al., Journal of Infection, 2024), greater antibody breadth and durability with successive Novavax doses via Matrix-M-driven epitope spreading (Lenart et al., npj Vaccines, 2024), and lower reactogenicity compared with mRNA vaccines (SHIELD-Utah study, 2025).
He has consistently positioned NVX-CoV2373 as the preferable option for long-COVID patients, vaccine-hesitant individuals, and those seeking a traditional protein-based platform, arguing these features address limitations observed with nucleic-acid vaccines. Supporters and coverage credit this multi-year pressure with helping secure the May 19, 2025 full approval, with efforts continuing into 2026 on access and distribution. These activities advocated for full Biologics License Application approval, pediatric indications, expanded access, and timely variant updates.
Critics of COVID-19 vaccines, including some vaccine-skeptical groups, have also opposed NVX-CoV2373 on the grounds that it contains the SARS-CoV-2 spike protein, which they have described as toxic or dangerous. In a 24 July 2022 post, physician Meryl Nass also criticized Matrix-M, the saponin adjuvant from Quillaja saponaria, which she treated as unused in a licensed vaccine and drawn from extracts with known toxicity, and the production of spike protein in moth cells. On 14 June 2021 Jane Ruby wrote that the Novavax vaccine contains a “dangerous spike protein” and “dumps millions of spike proteins into the body.” Brian Hooker, chief scientific officer of Children’s Health Defense, stated in a January 2022 article that the spike protein was likely to last a shorter time with Novavax than with the authorized vaccines, but that “since the spike protein has been consistently shown to create clotting issues in the blood, there are still concerns that need to be addressed and tracked.” Later commentary continued this criticism: Lynn Fynn, identified by the Independent Medical Alliance as a retired infectious disease specialist now focused on clinical research (online as @Fynnderella1), has described the spike protein in the Novavax COVID-19 vaccine as pathogenic; Tom Czerniawski (online as @BlackTomThePyr8) and the account Jikkyleaks (which originated the hashtag #Novagate on 18 August 2023) have opposed NVX-CoV2373 on the grounds that it contains the SARS-CoV-2 spike protein.
Access barriers further shaped public reception. Patient accounts circulating on social media from the 2023–2024 season through 2025–2026 described CVS systems replacing Novavax selections with Pfizer or Moderna, with some reporting that an mRNA vaccine was prepared, recorded, or administered unless the patient objected; those reports received no mainstream coverage and no public investigation statement from CVS. By contrast, The Sun and The Mirror reported a March 2025 CVS visit in Arlington, Virginia, in the opposite direction (Pfizer booking and email confirmations, Novavax listed on the pharmacist’s sheet and administered); CVS told The Mirror it had connected with the patient and would investigate, but no result was published. Advocates have framed these discrepancies — together with inconsistent staff information on Novavax’s distinct protein-subunit profile — as contributing to a self-fulfilling dynamic of lower visibility and uptake compared with mRNA options. Surveys indicated that while a subset of hesitant individuals expressed interest in protein-based vaccines for perceived lower risk of rare adverse events like myocarditis, overall acceptance remained constrained by timing and awareness, with no significant surge post-authorization. In Canada, the federal government's decision not to procure Novavax for the 2024-2025 respiratory season, citing low prior demand (only 5,529 of 125,000 ordered doses administered in 2023), drew criticism from immunocompromised individuals who experienced adverse reactions to mRNA vaccines and preferred non-mRNA options, with some traveling to the U.S. to obtain doses. Similar criticism came from small but vocal subgroups in the UK and Australia, including petitioners and online communities, who highlighted the lack of Novavax availability or choice amid preferences for non-mRNA options. UK phase 3 trial volunteers were among the first members of the public affected by approval delays: on 21 May 2021 The Guardian reported that participants threatened to withdraw because the still-unapproved vaccine did not appear on the NHS app as proof of vaccination, leaving them unable to travel to Europe. Later delays fueled online frustration among proponents, who viewed them as unnecessary hurdles, though general COVID-19 vaccine trust polls showed declining confidence unrelated specifically to Novavax.
Controversies and Criticisms
Manufacturing, Supply Chain, and Regulatory Delays
Adjuvant Sourcing & Sustainability
Novavax faced significant challenges in organizing and securing pharmaceutical raw materials and components during the early stages of the COVID-19 pandemic (2020–2021), which contributed to delays in scaling production, clinical trials, regulatory submissions, and global supply commitments. The company's NVX-CoV2373 vaccine relies on its proprietary Matrix-M adjuvant, a saponin-based compound derived from fractions of Quillaja saponaria (soapbark tree) bark extract, including the QS-21 component, formulated into nanoparticles with cholesterol and phospholipids. Saponins like QS-21 have historically faced supply limitations due to extraction from this single Chilean tree species, low yields, and sustainability concerns; Novavax's 2019 filings warned of potential delays without sufficient high-quality saponin extract. To address pandemic-scale needs, Novavax signed mid-2020 agreements with partners including AGC Biologics (Denmark/US), PolyPeptide Group (Sweden/California), and Desert King (for raw saponin sourcing) to ramp up production, though no major adjuvant-specific shortages halted progress. Broader industry-wide bottlenecks, such as shortages of single-use bioreactor bags critical for cell growth, further impacted antigen production scaling.
Emergent BioSolutions Contamination & Quality Failures
These upstream issues compounded manufacturing challenges during development and scale-up, primarily from quality control deficiencies and facility-specific problems. In April 2021, production at a contract manufacturing site operated by Emergent BioSolutions in Baltimore—Novavax's initial U.S. partner for scaling production—was halted by U.S. federal regulators for over three months due to contamination risks and quality control failures, affecting bulk drug substance output, disrupting early trial material production, and contributing to delays in vaccine availability. Despite receiving $1.6 billion in Operation Warp Speed funding in July 2020 to support late-stage clinical development, including Phase 3 trials, manufacturing scale-up, and provision of an alternative option for global supply—particularly over 2 billion doses to lower- and middle-income countries via COVAX, in contrast to the faster domestic rollouts enabled by mRNA platforms from Pfizer and Moderna—these problems were exacerbated by rapid scale-up under Operation Warp Speed, where processes began before full validation, leading to inconsistencies in yield and purity requiring remediation. U.S. officials expressed doubts about Novavax's scaling ability, with one source stating, "They rushed the process… It’s hard to make. And they can’t make it." This resulted in a pause on additional U.S. government manufacturing payments in August 2021—while overall development funding continued—until Novavax demonstrated compliance with FDA chemistry, manufacturing, and controls (CMC) and quality standards. While Operation Warp Speed provided broad support, including logistics embedding and addressing challenges across candidates, the government's response to Novavax's specific CMC and quality setbacks involved this funding hold pending resolution, rather than accelerated remediation—in contrast to the rapid at-risk scaling enabled for mRNA platforms that achieved first authorizations.
International Partner Delays
These international setbacks paralleled the scale-up difficulties encountered in U.S. production efforts earlier in the development timeline. Supply chain disruptions further compounded these issues, particularly with international partners. In July 2021, Novavax reported delays from ex-U.S. manufacturing collaborators attributed to recent laboratory-scale production errors, slowing antigen supply for filling and finishing. In Canada, the January 19, 2021 advance purchase agreement (APA) covered up to 76 million doses; on February 2, 2021, the government also announced a memorandum of understanding to pursue production at the National Research Council of Canada's Biologics Manufacturing Centre (BMC) in Montréal once the vaccine and the facility received Health Canada approval. A June 30, 2023 amendment forfeited and reduced scheduled doses (Canada agreed to pay $349.6 million for the forfeited doses), revised the delivery schedule, required BMC to produce bulk antigen for 2024 and 2025 doses, and allowed Canada to terminate the APA if Novavax did not obtain regulatory approval for vaccine made with BMC-produced antigen by December 31, 2024. Doses were delivered under the APA: the Public Health Agency of Canada began receiving 3.2 million Nuvaxovid doses in March 2022 and distributing them to provinces and territories, and in 2023 it ordered 125,000 doses of the XBB.1.5 formulation, of which 5,529 were administered; no vaccine was manufactured at the Montréal facility. For the 2024–2025 season, PHAC did not federally procure Nuvaxovid, citing low demand and stating that the contract provided access only to domestically manufactured vaccine, which Novavax had not confirmed for that season; provinces and territories could order internationally produced vaccine directly. On March 7, 2025, Canada terminated the APA with immediate effect because that BMC approval had not been obtained by the deadline; Novavax reported that $28 million in advance payments became refundable, that it expected to recognize about $576 million of previously deferred revenue and other liabilities as product revenue, and that a planned in-country investment memorandum, including $20 million in escrow, was no longer feasible. These setbacks led to unfulfilled advance purchase agreements, such as the 2021 Gavi deal, resolved via 2024 settlement with $75 million upfront and $80 million annual payments through 2028 for low-income country shortfalls.
Chemistry, manufacturing, and controls (CMC) hurdles, including batch-to-batch variability in nanoparticle formulation and adjuvant integration, delayed approvals and late market entry versus mRNA competitors. Critics attributed persistent issues to the protein-based platform's reliance on the Sf9 insect-cell baculovirus system for nanoparticle production, involving complex multi-step purification and stabilization, harder to industrialize quickly than nucleic acid vaccines despite over $1.6 billion in government funding. Allegations of broader contamination, including at a North Carolina adjuvant site, emerged in securities litigation, highlighting systemic oversight gaps during the rush, though Novavax stated resolved CMC challenges enabled later approvals. By 2023, these experiences informed operational shifts, but early bottlenecks eroded confidence in supply reliability for global efforts.
Novavax's path to regulatory approval took substantially longer than that of the mRNA vaccines at every major stage. From the initiation of its pivotal Phase 3 trial (PREVENT-19 on December 28, 2020) to emergency use authorization on July 13, 2022, Novavax required approximately 18.5 months. In comparison, both Pfizer-BioNTech and Moderna took approximately 4.5 months from the start of their Phase 3 trials (July 27, 2020) to EUA (December 11 and 18, 2020 respectively). These extended timelines were in significant part attributable to manufacturing setbacks outlined in the preceding section on manufacturing and supply chain issues.
Novavax's pursuit of emergency use authorization (EUA) for its COVID-19 vaccine, NVX-CoV2373, faced repeated postponements in submission to the U.S. Food and Drug Administration (FDA), initially planned for late 2021 but delayed due to manufacturing inconsistencies and the need for additional validation data from contract production sites, including challenges in scaling protein-based production at partners like the Serum Institute of India. These delays stemmed from manufacturing and chemistry, manufacturing, and controls (CMC) issues, including the downstream effects of the U.S. government's pause on additional manufacturing payments in August 2021 which reduced priority on remediation efforts, additional FDA data requests, heightened scrutiny of the protein-based platform, and platform-specific hurdles such as demonstrating batch-to-batch reproducibility. The EUA application was finally submitted to the FDA on February 1, 2022, supported by phase 3 trial data from the PREVENT-19 study showing 90.4% efficacy against symptomatic COVID-19.
The FDA's review process extended over four months, culminating in a positive recommendation from the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on June 7, 2022, after deliberations on manufacturing data and safety profiles. EUA was issued on July 13, 2022, for adults aged 18 and older—approximately 18 months after the January 28, 2021, announcement of positive interim Phase 3 results from the UK trial—compared to roughly 1 month for the Pfizer-BioNTech and Moderna mRNA vaccines from their November 2020 Phase 3 primary results announcements to EUA grants in December 2020, limiting availability during peak pandemic waves. Subsequent expansions, such as EUA for adolescents aged 12-17, were granted on August 19, 2022, after additional pediatric trial data, further illustrating incremental regulatory steps amid ongoing manufacturing scrutiny.
Full biologics license application (BLA) approval was granted on May 16, 2025, following missed FDA decision deadlines in April 2025. From EUA to full BLA approval, Novavax took approximately 34 months, versus 8 months for Pfizer-BioNTech (to August 23, 2021) and 13 months for Moderna (to January 31, 2022). Overall, mRNA vaccines achieved EUA and full approval in under 2 years from Phase 3 results, while Novavax took over 4 years, highlighting significant regulatory hurdles related to its technology. Following the full BLA approval, the FDA revoked the EUA on August 27, 2025. These episodes underscore how production-scale dependencies inherent to Novavax's technology prolonged timelines compared to nucleic acid-based alternatives, impacting market entry and revenue potential.
Internationally, regulatory outcomes varied. The European Medicines Agency (EMA) issued a conditional marketing authorization on December 20, 2021, enabling earlier deployment in the EU under the Nuvaxovid brand, though availability challenges persisted in some member states; following EMA authorization of the updated Nuvaxovid vaccine on October 9, 2024, for the 2024-2025 season, the vaccine was available and administered in Germany and Austria, with limited availability in Italy expiring in April 2025, and not broadly offered in Ireland due to procurement and demand issues. In Australia, despite an advance purchase agreement, no updated formulations have been approved or supplied since the original ancestral version's last batch expired on January 31, 2024; as of September 30, 2025, $31.3 million was classified as current deferred revenue and $102.6 million as non-current with respect to the Australia APA, which may be canceled if updated vaccine delivery deadlines are missed. Canada canceled its agreement in 2025 after missed deadlines. These delays also impacted trial participants; in May 2021, UK volunteers threatened to withdraw due to lack of approval for travel proof.
Critics allege that market pressures such as persistently high short interest and alleged trading microstructure manipulations represent another layer of systemic bias against Novavax’s protein-subunit platform, compounding the regulatory and access disparities previously outlined.
Cybersecurity
A United States Department of Justice indictment unsealed in July 2020 alleged that Chinese nationals attempted, on or about January 25 and 27, 2020, to break into a Maryland biotechnology firm and a Massachusetts biotechnology firm that were publicly known for COVID-19 vaccine work. The firms were not named.
Reuters reported on December 2, 2020, that suspected North Korean operators had, from September 2020, used websites mimicking online login portals in attempts against at least nine health organizations, including Novavax and Johnson & Johnson. The Wall Street Journal the same day reported that at least six pharmaceutical companies, including Novavax and Johnson & Johnson, had been targeted. Novavax spokeswoman Amy Speak said the company was aware of the threat and was coordinating with government agencies and private cybersecurity experts, and that the incursions did not pose a risk to the integrity of its data. Neither report established that a theft of data had occurred.
In its Form 10-K for the year ended December 31, 2025, filed February 26, 2026, Novavax stated in Item 1C that, as of that date, it had not experienced a cybersecurity incident that resulted in a material effect on its business strategy, results of operations, or financial condition. The same filing’s Item 1A, in the security-breaches risk factor that Item 1C cites, stated that like other companies in its industry, Novavax and third parties with connections to its systems or with data relevant to its business have experienced attacks on its data and systems, including malware and computer viruses.
A later case study published by the threat-intelligence firm Recorded Future quoted Nathalie Salisbury, a strategic threat intelligence analyst at Novavax, as saying that the platform reduced daily alerts from thousands to about ten, had on several occasions flagged vendor issues before the vendors themselves, and was used to protect vaccine intellectual property. The case study does not date the contract. Recorded Future received early investment from In-Q-Tel and in October 2024 announced that it had been selected as a cornerstone partner for the Office of the Director of National Intelligence's Sentinel Horizon program.
Allegations
Proponents argue that Novavax’s protein-subunit vaccine faced all the manufacturing, regulatory, procurement, and market obstacles described above despite clear scientific and clinical superiority over mRNA platforms. Critics claim this favoritism toward mRNA was driven by economic incentives: mRNA offered a high-margin, recurring-revenue booster model, a pattern some observers link to the 2018 Goldman Sachs analysis questioning whether “curing patients” (or highly effective preventives that shrink the recurring-revenue pool) is sustainable for pharma.
Allegations have been raised suggesting that Novavax's protein-subunit COVID-19 vaccine platform experienced stricter regulatory scrutiny, delayed approvals, and structural market disadvantages compared to mRNA-based vaccines developed by Pfizer-BioNTech and Moderna.
Technological and Clinical Advantages
Novavax's protein-based vaccine offers several important technological and clinical advantages over mRNA vaccines, including protein production via Sf9 insect cells for accurate antigen match, manufactured without fetal cell lines (unlike certain viral-vector platforms), Matrix-M adjuvant for robust B- and T-cell responses, lower side-effect burden, significantly lower rates of myocarditis and pericarditis compared with mRNA vaccines (particularly in adolescent and young adult males), avoidance of mRNA-specific risks such as persistent spike protein detection in rare cases up to 709 days post-vaccination,[249] an argument of lower cumulative circulating S1 exposure (area under the curve) because the protein vaccine supplies a fixed exogenous dose while mRNA vaccination and infection continue producing spike and shedding S1 (no study measured the integral; the only published concentration comparison is a day-1 macaque plasma level of 100–300 fg/mL after NVX-CoV2373, 10- to 333-fold below contemporaneous mRNA ranges of 10^{3}–10^{5} fg/mL on the same assay, with no human head-to-head circulating-spike data), no potential genomic integration via reverse transcription in vitro,[250] no ribosomal frameshifting,[251] and no lipid nanoparticle biodistribution including to gonadal tissues (unlike with mRNA vaccines),[252], absence of IgG4 class switching after repeated doses (unlike with mRNA vaccines), superior mucosal IgA induction, reduced waning, broader variant coverage in multiple studies, and a 2025 Korean real-world study demonstrating favorable effectiveness against any SARS-CoV-2 infection compared to BNT162b2 (Gwak et al.)[253].
In ancestral SARS-CoV-2 challenge studies, two doses of 5 µg NVX-CoV2373 (the later human antigen dose) with Matrix-M left no detectable subgenomic RNA in nasal swabs of cynomolgus macaques; one animal in the 5 µg group had bronchoalveolar-lavage sgRNA on day 2 that had cleared by day 4. In a separate rhesus macaque study, animals that received two doses of 5 µg or 25 µg had no detectable viral loads in bronchoalveolar lavage or nasopharyngeal swabs at any sampled day after challenge, and nasal-wash sgRNA was cleared by day 4.
Key results from the Phase 3 trials further illustrate these clinical advantages.
Pfizer-BioNTech BNT162b2 Phase 3 (Polack et al. NEJM 2020; Thomas et al. 6-month follow-up)
- Trial: July 27 – Nov 14, 2020 (primary cutoff); ~44k participants.
- Predominant strain: original Wuhan/ancestral (Alpha just emerging).
- Symptomatic COVID-19: ~95% efficacy
- Severe COVID-19: 1 vs 9 (primary analysis) → 1 vs ~30 (6-mo blinded)
- Hospitalizations/COVID deaths in vaccine arm: occurred (small number)
Novavax NVX-CoV2373 PREVENT-19 Phase 3 (Dunkle et al. NEJM 2021/2022)
- Trial: Dec 27, 2020 – Apr 19/30, 2021; ~30k adults (US/Mexico).
- Predominant variants: Alpha (B.1.1.7) dominant; 79% of sequenced cases VOC/VOI.
- Symptomatic COVID-19: 90.4% efficacy (14 vs 63 placebo) — all vaccine breakthroughs mild
- Moderate-to-severe COVID-19: 0 vs 14 (100% efficacy)
- Hospitalizations/COVID deaths: 0 in vaccine arm (all in placebo)
These outcomes highlight Novavax’s strong performance against severe disease and hospitalization in its trial setting.
The Pfizer-BioNTech trial took place earlier (July–November 2020) when the ancestral Wuhan strain predominated with Alpha just emerging. In contrast, the Novavax PREVENT-19 trial was conducted later (December 2020–April 2021) when the more transmissible Alpha variant had become dominant.
These were not head-to-head studies, but the variant difference is important because Novavax showed high efficacy against a more evolved strain than the one predominantly circulating during the Pfizer trial. Novavax had these superior results even though its trials took place at a later point facing variants with greater evasion of immunity.
A further clinical advantage emerges from a 2026 systematic review and meta-analysis conducted by researchers at the University of Toronto (Krishnan et al., Eye), which identified an association between mRNA COVID-19 vaccines and increased risk of ocular complications—particularly retinal vascular occlusion—in the first month post-vaccination. This specific safety signal has not been observed with protein-subunit vaccines like Novavax's NVX-CoV2373, reinforcing the technological and clinical superiority of the protein-based platform regarding certain rare adverse events. Krishnan et al., 2026 (opens in a new tab)
Transmission Prevention and Herd Immunity Potential
Proponents of these allegations emphasize Novavax's potential advantages in preventing transmission and promoting herd immunity, stemming from its induction of robust mucosal IgA in the respiratory tract. This may enable superior "sterilizing immunity" by blocking initial viral infection at the mucosal entry point, reducing not only symptomatic disease but also asymptomatic carriage and onward transmission—unlike intramuscular mRNA vaccines, which primarily elicit systemic humoral and cellular responses with more limited mucosal IgA. This is supported by preclinical and clinical data showing stronger nasal and salivary IgA responses with Novavax's protein subunit platform and Matrix-M adjuvant. A 2025 Korean real-world effectiveness study (Gwak et al.)[253] reported higher relative effectiveness against any SARS-CoV-2 infection (including asymptomatic) for NVX-CoV2373 compared to BNT162b2, suggesting greater potential to interrupt transmission chains. At the population level, these characteristics could translate to stronger herd immunity effects, more effectively reducing community viral circulation, protecting unvaccinated or vulnerable individuals through indirect immunity, and mitigating epidemic resurgence compared to vaccines optimized mainly for preventing severe outcomes while permitting breakthrough infections and transmission.
However, this transmission-blocking potential was never the primary design goal of the dominant mRNA platforms, whose original Phase 3 trials focused only on preventing symptomatic disease. Former German Health Minister Jens Spahn testified before the Bundestag Enquete-Kommission that preventing transmission was never the primary goal in the development or procurement of COVID-19 vaccines.
Nevertheless, German government communications and public statements by Spahn and Lauterbach repeatedly emphasized that vaccination would protect not only the individual but also others (‘Impfung schützt andere’), framing high uptake as essential to stopping community spread and justifying mandates and restrictions. The argument of transmission prevention was frequently invoked in public communications to justify vaccination mandates and related measures. This points to a noted discrepancy between the primary objectives of the vaccines (protection against severe disease) and the broader narratives used to promote their uptake.
On October 1, 2026, Florida Attorney General James Uthmeier filed a lawsuit against Pfizer Inc. and its CEO Albert Bourla in St. Lucie County under the Florida Deceptive and Unfair Trade Practices Act, alleging that the company urged people to take its COVID-19 vaccine to protect others although it had not tested whether the vaccine stopped transmission. Pfizer said the allegations have no merit and that its representations were accurate and science-based.
Public-Health Implications (Long COVID burden)
This capability is particularly important because even mild SARS-CoV-2 infections can trigger systemic bodily and organ damage—including persistent cognitive deficits such as memory loss and brain fog (equivalent to 3–9 IQ-point losses in large population studies) and chronic respiratory impairment such as shortness of breath/dyspnea—contributing to Long COVID and sustaining demand for therapeutics and chronic-care products. Global economic analyses estimate the annual burden of Long COVID at roughly $1 trillion (with some models reaching $3.7 trillion when including quality-of-life and productivity losses), or approximately 1% of world GDP. If widely adopted, such a vaccine could have reduced these long-term health risks and the demand for repeated boosters.
As of February 2026, Germany’s Robert Koch Institute (RKI) continues to describe Long COVID as an ongoing public-health challenge with major long-term consequences for individuals, the healthcare system, and society at large, with symptoms persisting in an estimated 10–15 % of adults and approximately 15 % of affected individuals still symptomatic after one year. A new OECD report published in April 2026 (“Addressing the Costs and Care for Long COVID”) projects that Long COVID will impose an ongoing annual economic burden of up to $134 billion across OECD countries over the next decade (2025–2035), equivalent to 0.1–0.2 % of GDP. Of this total, direct healthcare costs are estimated at approximately $11 billion per year, while the vast majority stems from indirect costs such as lost productivity, absenteeism, and reduced labor-force participation.
Alleged Financial Interests Favoring mRNA Platform
Allegations suggest that unequal treatment of Novavax is linked to the U.S. government’s financial stake in mRNA platform success via NIH patents on the prefusion-stabilized spike protein (the “2P” stabilization used in the Pfizer-BioNTech, Moderna, and Novavax COVID-19 vaccines).[194] Moderna paid the NIH $400 million in 2023 (plus ongoing low single-digit royalties),[195] while BioNTech settled in December 2024 for $791.5 million (Pfizer reimbursed $364.5 million), also agreeing to continuing royalties. These disparities in royalty distributions purportedly favor mRNA developers.
A parallel royalty stream arises from University of Pennsylvania patents on nucleoside-modified mRNA technology developed by Drew Weissman and Katalin Karikó, which was licensed to Moderna and BioNTech. Moderna paid Cellscript LLC (the Penn sublicensee) $641 million in 2021 and $635 million in 2022, with Penn entitled to a share of those royalties plus ongoing low single-digit royalties. BioNTech paid the Hospital of the University of Pennsylvania $1.6 billion in royalties from 2021 to 2023 according to CMS Open Payments data and settled additional 2020–2023 claims for $400 million (Pfizer reimbursing $170 million), with continuing royalties. As a recombinant protein vaccine, Nuvaxovid does not use the modified-mRNA technology and generates no such payments to the University of Pennsylvania.
In the United States, a Business Insider analysis of congressional financial disclosures found that at least 75 federal lawmakers (or their spouses) held shares in Moderna, Pfizer, or Johnson & Johnson in 2020 during the COVID-19 pandemic. Critics allege that such holdings created potential conflicts of interest, contributing to favoritism toward mRNA-based platforms over Novavax's protein-subunit vaccine.
Examples include Rep. Josh Gottheimer (D-NJ), who held Moderna shares and sold up to $15,000 worth in May 2020; Rep. Marie Newman (D-IL) and her husband, who held shares in Moderna and Johnson & Johnson; Sen. Tommy Tuberville (R-AL), who held Johnson & Johnson shares; and multiple other lawmakers with Pfizer holdings of significant collective value. In 2022 reports, Democratic congressional candidate Jay Chen (California) was found to have failed to disclose investments in Pfizer and Moderna stocks, purchased in late 2020 just before the mass vaccine rollout, on his required federal financial disclosure form for congressional candidates. He had disclosed the holdings on a California state form but omitted them federally, amending the disclosure only after Business Insider contacted his campaign with proof of the investments. Critics cite this as another example of potential financial interests in mRNA platforms among political figures during the pandemic.
In the United Kingdom, critics have pointed to former Chancellor and Prime Minister Rishi Sunak’s co-founding of hedge fund Theleme Partners — which held a roughly $500–710 million stake in Moderna (up to 34 % of its portfolio) — as raising questions of potential conflict of interest, given the government’s subsequent major Moderna supply contracts and 10-year strategic partnership while taking a more restrictive stance on Novavax variant-update authorizations.
Allegations of Unequal Regulatory Scrutiny and Delays
As NIAID Director and a senior advisor during Operation Warp Speed, Anthony Fauci played a major role in shaping U.S. COVID-19 vaccine strategy. Critics argue his strong support for mRNA platforms contributed to faster regulatory pathways for Pfizer and Moderna, while Novavax encountered longer approval timelines and greater market obstacles despite receiving $1.6 billion in Operation Warp Speed funding.
In a November 2025 interview on the Dana Parish podcast, former CDC Director Robert Redfield alleged that FDA official Peter Marks delayed Novavax's approval by requiring an unnecessarily high purity level beyond the 85% achieved by the company, attributing this partly to politics and approval processes favoring mRNA vaccines, while praising Novavax as a safer protein-based option compared to mRNA shots.
At the 7 June 2022 Vaccines and Related Biological Products Advisory Committee meeting on Novavax's EUA request, Marks stated, “We take manufacturing very seriously,” and “We don’t benchmark ourselves against other countries when it comes to manufacturing, we consider that we have a very high standard.” The EMA had recommended Nuvaxovid on 20 December 2021.
In the March 19, 2026, testimony before the German Bundestag Enquete-Kommission (Kommissionsdrucksache 21(27)30), former Pfizer Chief Toxicologist Dr. Helmut Sterz criticized the safety testing for the mRNA vaccine Comirnaty as inadequate, noting the absence of standard preclinical studies including dose-finding, reproductive toxicity, and subchronic toxicity assessments in violation of international guidelines (ICH, EMA, FDA). He contrasted this abbreviated process with the full preclinical testing required for Novavax's protein-based vaccine. For example, the EMA's assessment report for Comirnaty noted decreased RNA integrity and higher levels of truncated or modified mRNA forms in initial Process 2 (commercial scale-up) batches compared to Process 1 (clinical/trial) material.[234] Ongoing claims in independent analyses and testimony point to higher residual DNA contamination in commercial versions without equivalent full clinical testing equivalent to the trial material.[235] A later formulation change from PBS/sucrose to Tris/sucrose buffer for improved refrigerated stability was approved based on comparability data rather than new trials.
FDA official Peter Marks' June 2024 override of certain VRBPAC concerns to favor updating to the KP.2 variant has been cited by critics as evidence of preferential treatment for mRNA platforms.
Novavax remained under Emergency Use Authorization (EUA) until full Biologics License Application (BLA) approval on May 16, 2025, while Pfizer and Moderna had received full BLA approval in 2021–2022. The prolonged EUA status restricted direct-to-consumer advertising, hindered negotiations for broad commercial contracts and stocking agreements with major pharmacy chains, and slowed full integration into routine insurance reimbursement and private-market distribution.
In August 2025, then-CBER Director Vinay Prasad attached postmarketing commitments to the COVID-19 vaccine approvals that included randomized, placebo-controlled studies in adults 50–64 years of age without high-risk conditions. For Nuvaxovid this included a Phase 4 observer-blind placebo-controlled trial evaluating circulating vaccine-derived spike protein; analogous circulating-spike analyses were also attached as substudies of the mRNA manufacturers’ 50–64 randomized trials. After Prasad’s departure from the FDA in April 2026, the FDA on 27 August 2026 approved a supplement (STN BL 125817/131) to the Biologics License Application for the 2026–2027 Formula of NUVAXOVID, manufactured at the Serum Institute of India Private Limited facility in Pune for Sanofi Vaccines US, and released the sponsor from the prior postmarketing commitment (PMC 2 under STN BL 125817/6) for a Phase IV observer-blind, placebo-controlled trial of circulating vaccine-derived spike protein in adults 50–64 years of age, citing operational and feasibility challenges that impacted conduct of the study as originally designed. The commitment was replaced with a nonclinical study to assess biodistribution and persistence of vaccine-derived spike protein and a Phase 4 retrospective integrated analysis of NUVAXOVID clinical-trial data evaluating symptom clusters potentially consistent with post-COVID vaccination syndrome. Critics have cited the imposition and subsequent withdrawal of the requirements as an illustration of inconsistent post-approval scrutiny.
International Regulatory
The pattern of regulatory and market bias extended internationally. Although the vaccine received regulatory approvals starting in late 2021 and 2022, including the EMA conditional marketing authorisation in December 2021, provisional approvals in Australia and New Zealand, and authorisations in the UK and Canada, it remained niche or unavailable in most national immunisation programmes, with very low uptake compared to mRNA vaccines secured through much larger early procurement contracts. Canada terminated its advance purchase agreement in March 2025 after a missed December 31, 2024 deadline for approval of vaccine made with BMC-produced antigen, though doses had previously been delivered; Australia cancelled 2025 doses and Novavax withdrew its updated TGA application in July 2025 at the request of or based on recommendations made by the TGA, as stated in the company's SEC filings,[239] which caused Australia to miss the December 31, 2025, contractual deadline for updated doses (with a March 31, 2026, termination deadline approaching), risking cancellation of up to 3 million credited doses and up to $92.5 million in deferred revenue becoming refundable; New Zealand settled its agreement with refunds; the UK did not authorize the updated 2024/25 vaccine, resulting in no ongoing availability.
An internal Health Canada assessment later released under access-to-information file A-2023-000979 recorded that Pfizer’s reply to a 4 August 2023 quality clarification identified an SV40 promoter and an SV40 poly(A) sequence on the plasmid used to manufacture Comirnaty. Reviewers disagreed with the sponsor’s justification, noting that plasmid-derived DNA fragments remain in the final product as a process-related impurity and that the plasmid therefore should not include unnecessary DNA regulatory elements, which at a minimum should have been disclosed at the initial filing. On 24 August 2023 Health Canada strongly recommended removal of those elements from plasmids used for future variant vaccines; the sponsor agreed only to evaluate the request further. Pfizer confirmed the sequences to Health Canada on 9 August 2023 during review of the XBB.1.5 submission. Comirnaty had been authorised in December 2020. Health Canada authorised the XBB.1.5 vaccine in September 2023 and the KP.2 update in September 2024. A 25 November 2024 parliamentary answer stated that, beyond the mRNA coding for the new strain, the formulation was unchanged.
Procurement Biases
Uptake remained very low across much of the EU despite conditional approvals. Observers have pointed to the European Commission’s €35 billion contract for up to 1.8 billion doses with Pfizer-BioNTech — negotiated in part via private text messages between President Ursula von der Leyen and Pfizer CEO Albert Bourla that later could not be located — as part of a broader preference for mRNA platforms.[240] This contract significantly exceeded the EU’s separate advance purchase agreement with Novavax (up to 200 million doses, signed August 2021). The affair, known as “Pfizergate,” led to a May 2025 EU General Court ruling that the Commission violated transparency rules.
Alleged Impact on Patients with Contraindications to mRNA Vaccines
Critics allege that the delayed regulatory approvals, limited procurement, low promotion, and supply constraints for Novavax's COVID-19 vaccine disproportionately harmed individuals medically intolerant to mRNA platforms. This subpopulation includes those with documented contraindications or precautions, such as polyethylene glycol (PEG) allergy (a component in mRNA vaccines but absent in Novavax), history of anaphylaxis to mRNA vaccine components, or heightened risk of myocarditis/pericarditis following mRNA vaccination.
Official guidance from the U.S. Centers for Disease Control and Prevention (CDC) and the American Academy of Allergy, Asthma & Immunology (AAAAI) explicitly recommends Novavax as an alternative or preferred option for these patients, recognizing its protein-based nanoparticle platform and Matrix-M adjuvant as providing a distinct safety profile without PEG-related risks.
Allegations assert that the systemic deprioritization of Novavax—manifested in delayed full approvals, restricted market access, and minimal integration into vaccination programs—effectively deprived this clinically vulnerable group of their primary evidence-based non-mRNA option. Critics argue this turned alleged biases in regulatory scrutiny, procurement favoritism, and marketing power into tangible medical harm, including potential increased risk of COVID-19 complications, vaccine avoidance, or limited informed choice for those unable to safely receive mRNA vaccines. This patient-safety and equity concern is presented as a distinct consequence not fully addressed in other platform-bias allegations.
Pharmacy-Level Distribution Obstacles
The prolonged EUA status hindered negotiations for broad commercial contracts and stocking agreements with major pharmacy chains, and slowed full integration into routine insurance reimbursement and private-market distribution.
In 2023 Novavax was supplied in multi-dose vials, exposing pharmacies to waste risk and causing many to skip stocking it entirely.
For the 2024–2025 season, the primary contracting window for major chains fell in January–April, when Novavax still held only EUA status and had a short shelf-life; the distributor Sanofi therefore placed minimal orders, producing frequent shortages and late-season unavailability.
Operational friction compounded the problem: corporate inventory systems often failed to reflect in-store stock, and near-expiry doses were routinely returned weeks early.
In the 2023–2024 season, CVS's online scheduler listed Pfizer or Moderna and instructed patients who wanted Novavax to speak with a pharmacist; pharmacists commonly told patients to book an mRNA appointment and request Novavax in store. During the 2024–2025 season, patients, a clinician, and pharmacy staff reported that CVS replaced Novavax selections with Pfizer or Moderna; some visits ended with an mRNA vaccine prepared or recorded, and patients reported administration of Pfizer or Moderna unless they objected. Those reports of mRNA product given after a Novavax selection received no mainstream coverage and no public CVS investigation. In March 2025, The Sun and The Mirror US reported a visit at a CVS in Arlington, Virginia, in the opposite direction: the patient had signed up for Pfizer and received emails and reminders confirming Pfizer, while the pharmacist's sheet listed Novavax, and she said the injection followed that sheet; CVS told The Mirror it had connected with the patient and would investigate, but no result was published. In late September and early October 2025 the same booking omission was reported, and some stores administered Novavax after the patient asked or after a refrigerator check. In September 2026 the booking page listed Pfizer and Moderna at locations the Novavax finder listed as CVS, and one patient reported that staff showed a Nuvaxovid box and the pharmacist prepared Pfizer.
In each case the practical barriers stood in sharp contrast to the earlier full approval, longer shelf-life, and pre-filled single-dose format that mRNA products enjoyed from the outset of their commercial seasons.
Alleged Media Control Favoring mRNA Platform
mRNA Advertising and Marketing Power
These disadvantages were exacerbated by Novavax’s significantly smaller advertising and marketing budget. Novavax reported advertising costs of $8.9 million in 2021 and $84.0 million in 2022, and its Form 10-K noted that emergency-use authorization conditions included restrictions on advertising and promotion. Pfizer reported company-wide advertising expenses of approximately $2.0 billion in 2021 and $2.8 billion in 2022, covering all of its products. Moderna described its 2021 advertising expenses as immaterial and reported $121 million in 2022. There was also a regulatory asymmetry in what each company could say in advertising. Pfizer-BioNTech's Comirnaty received full FDA approval on 23 August 2021 and Moderna's Spikevax on 31 January 2022, whereas Novavax's vaccine remained under emergency use authorization in the United States until 16 May 2025. Under its EUA, every Novavax advertisement and promotional item had to state "clearly and conspicuously" that the vaccine "has not been approved or licensed by FDA," had to be filed with FDA at first use, and had to be withdrawn if FDA objected. Pfizer began television advertising for its vaccine in December 2021, after full approval. In September 2022, Comirnaty was the fourth-largest drug brand on U.S. national television, with an estimated $16.7 million in spend that month, more than 63% of it placed during NFL broadcasts, according to iSpot.tv data reported by Fierce Pharma.
Board interlocks between pharma, media and platforms
These spending differences were potentially reinforced by institutional overlaps such as James C. Smith serving as President and CEO of Thomson Reuters until March 2020 while simultaneously serving as a member of Pfizer's Board of Directors since June 2014; he subsequently chaired the Thomson Reuters Foundation until May 2026. The Foundation provides core funding to the Reuters Institute for the Study of Journalism. A second overlap involved Scott Gottlieb, a Pfizer director since June 2019 and a CNBC contributor, who also sat on the board of National Resilience, Inc.; in September 2021 Resilience signed a multi-year agreement to manufacture mRNA for Moderna’s COVID-19 vaccine.
In August 2021 Gottlieb emailed Twitter senior public-policy manager Todd O’Boyle about a tweet by former acting FDA commissioner Brett Giroir stating that COVID-19 natural immunity was superior to vaccine-induced immunity; Gottlieb described the post as “corrosive” and said it would “end up going viral and driving news coverage.” Twitter subsequently labeled the tweet misleading and restricted likes, replies, and shares.
A further overlap involved Susan Desmond-Hellmann, a Facebook director from 2013 until 30 October 2019, during which time she was also chief executive of the Bill & Melinda Gates Foundation; she joined Pfizer's board on 2 April 2020. In September 2019 the Gates Foundation took a $55 million equity stake in BioNTech, citing the company's mRNA-based approach.
Government campaigns and mRNA-default recommendations
Government and donated-media campaigns also promoted COVID-19 vaccination during 2021 and early 2022, when the only widely available U.S. products were the Pfizer-BioNTech and Moderna mRNA vaccines and, from February 2021, Johnson & Johnson’s viral-vector vaccine; Novavax did not receive U.S. emergency-use authorization until July 2022. The Department of Health and Human Services “We Can Do This” campaign spent approximately $276 million on paid media from April 2021 to January 2022.00110-7/fulltext) The Ad Council’s “It’s Up To You” vaccine-education campaign, developed in partnership with HHS and the Centers for Disease Control and Prevention, received donated advertising inventory from platforms including Facebook and Google/YouTube.
Official recommendations and subsequent paid campaigns also treated mRNA products as the default option. In December 2021 the CDC adopted a “clinical preference” for mRNA vaccines over Johnson & Johnson’s viral-vector vaccine, keeping the latter for individuals “unable or unwilling to receive an mRNA vaccine.” When HHS launched a fall 2022 phase of the “We Can Do This” campaign urging Americans to get an “updated vaccine,” the updated products then available were the Pfizer-BioNTech and Moderna bivalent boosters; television spots began during programs including Good Morning America and Jimmy Kimmel Live. Novavax’s booster, authorized on 19 October 2022, was limited to adults for whom an mRNA bivalent booster was “not accessible or clinically appropriate” or who “would otherwise not receive a booster dose.” In the 2023–24 season, CDC’s 12 September 2023 recommendation named the updated COVID-19 vaccines from Pfizer-BioNTech and Moderna. Novavax’s updated formula was authorized three weeks later, on 3 October 2023.
Fact-checking partnerships and the Trusted News Initiative
Reuters launched its Fact Check unit in February 2020 as a paid partner in Facebook’s third-party fact-checking program. Reuters’ Trust Principles, overseen by the Thomson Reuters Founders Share Company, are intended to preserve editorial independence and freedom from bias.
Deutsche Presse-Agentur (dpa) has been a paid Meta third-party fact-checker for Germany since March 2019 and for Austria and Switzerland from May 2020; its fact-checks are also issued on the agency wire for use by clients of dpa, a GmbH with around 170 shareholders (mainly newspaper and magazine publishers and broadcasters). Google’s News Initiative funded dpa’s Faktencheck21 journalist-training programme. The Federal Ministry of the Interior granted dpa subsidiary UseTheNews gGmbH up to €1 million for the 2023–24 “Year of News” news-literacy campaign.
The same piece highlighted that FDA was concerned myocarditis "could be more frequent with Novavax than after mRNA vaccination."
The Trusted News Initiative, a BBC-founded partnership launched on 7 September 2019 after a June 2019 summit, whose members included Thomson Reuters, the Associated Press, Agence France-Presse, The Washington Post, Meta, Google/YouTube, the European Broadcasting Union (EBU), First Draft, and the Reuters Institute for the Study of Journalism, coordinated rapid alerts on content classified as COVID-19 vaccine disinformation beginning in 2020. In March 2020 the EBU stated that its Eurovision Social Newswire team was in direct contact with the TNI framework and that any critical alerts would be disseminated to EBU members by the EBU’s News Unit. In December 2020 the partners agreed to focus on combating what they described as harmful vaccine disinformation, alerting one another to disinformation that posed an immediate threat to life so that platforms could review content promptly and publishers would not unwittingly republish it. The BBC World Service Group funded research led by the Reuters Institute working with First Draft on the effectiveness of interventions against health disinformation.
Media framing of Novavax as a latecomer
At the July 2022 U.S. emergency use authorization, major outlets framed Novavax as a latecomer that had overcome manufacturing problems and was authorized only as a two-dose primary series for adults.
The New York Times used “a Latecomer” in its headline and wrote that the vaccine had “finally overcome manufacturing problems” and was authorized as a primary immunization series rather than a booster, which “may limit its market at first.”
The Washington Post described the company as “a straggler in the vaccine race,” while Politico, Reuters, and STAT positioned the protein-subunit shot as a more traditional option that might appeal to remaining unvaccinated adults and people hesitant about mRNA vaccines rather than as a competing platform.
Later articles in the same outlets continued this framing: a 2023 KFF Health News headline still called it the “Latecomer Covid Vaccine,” and a 2025 New York Times approval story again presented Nuvaxovid as a traditional alternative for people wary of mRNA technology, without discussing comparative mucosal, circulating-S1, or reactogenicity findings.
Censorship and content moderation on social-media platforms
Broader allegations of content moderation and censorship on social media platforms, purportedly favoring a pro-mRNA narrative, have been associated with German content-moderation networks mapped in Liber-Net’s report The Censorship Network: Regulation and Repression in Germany Today (version 1.5, April 2026). That edition’s only Germany-specific pharmaceutical example is a sentence citing journalist Lee Fang’s Twitter Files reporting that Twitter sought to shield Pfizer from criticism in order to increase uptake of its mRNA vaccine.
During the pandemic, such moderation in Germany and the EU took place under the Network Enforcement Act (NetzDG) of 2017 and the EU COVID-19 disinformation monitoring programme launched in June 2020, which added a vaccine-specific focus in January 2021; the EU Digital Services Act entered into force only on 16 November 2022.
These allegations sit alongside BioNTech’s significant political and economic influence in Germany—where the company’s vaccine sales contributed up to 0.5 percentage points to national GDP growth in 2021—and the RKI leak, which revealed instances of political pressure overriding scientific discussion at Germany's Robert Koch Institute on vaccine policy and public messaging. Similarly, Alena Buyx, Chair of the German Ethics Council, was a prominent public advocate for mRNA-based vaccines; she publicly criticized footballer Joshua Kimmich’s hesitation over mRNA long-term safety concerns and repeatedly endorsed high vaccination uptake as an ethical and collective responsibility.
Pharmaceutical-industry pressure on platforms
Additionally, a January 2023 installment of the Twitter Files by journalist Lee Fang documented two channels of pharmaceutical-industry pressure on Twitter concerning COVID-19 vaccine content. BioNTech asked Twitter to hide tweets targeting its account during a planned #PeoplesVaccine action advocating intellectual-property waivers and generic manufacture; the request was conveyed through Germany’s Federal Office for Information Security (BSI), which characterized the campaign as a potential distributed-denial-of-service (DDoS) attack.
Separately, the Biotechnology Innovation Organization (BIO) provided $1,275,000 to Public Good Projects’ “Stronger” campaign, which sent Twitter regular lists of tweets recommended for action. Novavax directors Margaret G. McGlynn and Rachel King served on BIO’s board of directors and executive committee; Novavax itself publicly opposed the proposed WTO TRIPS waiver for COVID-19 vaccines.
US government pressure on platforms
Alleged patterns of favoritism toward the mRNA platform occurred against the backdrop of documented efforts to influence public narratives on COVID-19 vaccines and suppress dissenting information.
Repeated instances of US government pressure on social media platforms to moderate content related to COVID-19 vaccines were revealed in the Twitter Files and litigated in Murthy v. Missouri; the U.S. Supreme Court held in June 2024 that the plaintiffs lacked Article III standing and therefore did not reach the merits of the First Amendment claims.
Internal emails (released via lawsuits like Missouri v. Biden) and Meta's own disclosures show senior Biden administration officials (White House, Surgeon General) repeatedly pressed Facebook/Meta to remove or restrict COVID-19 posts on vaccine criticism, lab-leak theory, and hesitancy. One example: a senior White House official demanded removal of a satirical meme mocking vaccines.
After President Biden publicly accused Facebook of “killing people” for not doing enough, Meta executives met urgently with officials, changed policies, and removed pages/groups/accounts flagged by the administration. In an August 2024 letter Zuckerberg wrote that the pressure was “wrong” and that officials expressed “a lot of frustration” when Meta didn’t fully comply on certain COVID content, including humor, but added that “ultimately, it was our decision whether or not to take content down, and we own our decisions.”
Platform policies
In February 2021, Instagram permanently removed RFK Jr.’s personal account for “repeatedly sharing debunked claims” about COVID-19 vaccines (including mRNA-related safety concerns).[npr.org (opens in a new tab)] Meta also restricted or removed accounts of his organization, Children’s Health Defense, which criticized mRNA platforms and highlighted alternatives or injury reports.
This was part of Meta’s broader “Disinformation Dozen” crackdown, where 12 high-profile accounts (many questioning mRNA or promoting non-mRNA options) were hit with removals, reach limits, or ad bans. Facebook/Instagram labeled or throttled posts discussing vaccine risks, DNA/RNA alteration fears, or comparative platform data.
YouTube (owned by Google) implemented and expanded policies starting in 2020 to ban content that contradicted guidance from local health authorities or the World Health Organization (WHO) on the safety, efficacy, or ingredients of approved vaccines, including unsubstantiated claims that vaccines cause autism, cancer, infertility, or other serious conditions. This policy, initially focused on COVID-19 vaccines and later broadened to all vaccines, resulted in the removal of over 30,000 videos containing COVID-19 vaccine misinformation by March 2021, with further removals scaling up significantly.
Prominent critics of COVID-19 vaccines, including Joseph Mercola, Robert F. Kennedy Jr., and Sherri Tenpenny, had channels banned, demonetized, or had content removed for alleging mRNA-specific risks or promoting non-mRNA alternatives and treatments. Allegations claim this disproportionately suppressed discussions questioning mRNA platforms or highlighting potential issues like myocarditis, waning efficacy, or comparative studies favoring protein-subunit vaccines, while enforcing official narratives that were predominantly mRNA-centric during the pandemic.
YouTube removed 30,000 videos with vaccine misinformation (opens in a new tab)
YouTube bans all anti-vaccine misinformation (opens in a new tab)
YouTube bans misleading Covid-19 vaccine videos (opens in a new tab)
Institutional and regulatory opacity / narrative control
For instance, FOIA-obtained internal documents revealed that CDC researchers revised a 2022 study published in The Lancet Infectious Diseases on mRNA vaccine safety, removing death-related results from the abstract and shifting detailed death data to supplemental materials.
Similarly, Australian TGA FOI 4558 released a 78-page COVID vaccine batch-testing report that was almost entirely redacted, with only one Pfizer Comirnaty lot number (FG0050) visible. Independent analyses link this lot to clusters of serious adverse events and deaths in Australia.
Similarly, in Germany, the federal government and RKI have been accused of withholding SafeVac and Kava vaccine-damage data, while heavily redacting COVID crisis-team minutes on vaccine safety before a major unredacted leak surfaced.
Similarly, in 2021–2022, the FDA proposed releasing Pfizer’s COVID-19 vaccine licensing and safety data (over 450,000 pages from clinical trials, manufacturing, and adverse events) at only 500 pages per month—a timeline exceeding 75 years—while planning extensive redactions for claimed trade secrets and privacy reasons. Following a lawsuit by Public Health and Medical Professionals for Transparency, a federal judge ordered a substantially faster release schedule.
Additionally, the CDC heavily redacted FOIA-released documents related to myocarditis and post-vaccination deaths; unredacted versions obtained via a 2025 Senate subpoena by the Permanent Subcommittee on Investigations (chaired by Sen. Ron Johnson) revealed internal CDC discussions highlighting deaths reported after vaccination as of "particular interest," myocarditis signals in young males, and limitations in V-safe data that were downplayed publicly.
The UK's MHRA and other regulators have faced similar criticisms for heavily limited or redacted FOI responses on Yellow Card adverse event reports and batch-specific data, mirroring issues in the TGA FOI 4558.
Alleged Bias from Medical Experts Favoring mRNA Platforms or Dismissing Novavax's Protein-Subunit Platform and Matrix-M Adjuvant
Prominent medical experts have aggressively promoted mRNA COVID-19 vaccines, routinely dismissing or downplaying serious long-term safety concerns tied to the novel mRNA platform, while deliberately ignoring or outright dismissing Novavax's protein-subunit vaccine and Matrix-M adjuvant as legitimate—or even superior—alternatives. For example, Neil Stone, who frequently presents himself as a defender of science, has maintained nearly five years of complete silence on Novavax and the Matrix-M adjuvant while relentlessly defending and promoting mRNA vaccines on an almost daily basis. He has repeatedly issued unsubstantiated claims that non-mRNA vaccines are “less effective and less safe” without providing any supporting scientific evidence. Stone was an especially aggressive advocate for mRNA vaccines during the pandemic, vociferously pushing their widespread use, dismissing valid long-term safety concerns about the experimental mRNA technology, and systematically marginalizing or ignoring Novavax’s established protein-subunit platform and Matrix-M adjuvant across his public statements, interviews, and commentary. This pattern is especially notable given Stone’s routine public criticism of Robert F. Kennedy Jr. (RFK Jr.) on nearly every other vaccine issue, where he has repeatedly labeled RFK’s positions as “anti-science” or worse. Yet when RFK Jr. publicly stated in April 2025 that single-antigen vaccines like Novavax “have never worked” for respiratory illnesses (in the context of delaying its full FDA approval), Stone offered no rebuttal or comment—consistent with his broader silence on the Novavax platform itself. This blatant selective advocacy and clear bias has substantially contributed to sidelining protein-subunit approaches in expert-led public health narratives, entrenching one-sided favoritism toward the mRNA platform and illustrating broader patterns of narrative control by medical experts.
Another example is Robert Malone, a prominent critic of mRNA COVID-19 vaccines. Earlier in the pandemic, Malone advocated for Novavax's protein-subunit vaccine as the leading non-mRNA alternative, praising its potential as a safer and more traditional option compared to mRNA platforms. However, he has since shown near-total silence and non-engagement regarding Novavax's protein-subunit vaccine—the only non-mRNA COVID-19 vaccine approved in multiple jurisdictions. Malone has been critical of current adjuvant technology in general. Despite this, when directly questioned about Novavax’s Matrix-M adjuvant — which is considered superior to existing adjuvant platforms — he dismissed it as having unspecified issues and claimed that GSK’s adjuvant portfolio is superior, without providing any supporting scientific literature or data. This drastic turn from initial advocacy to selective criticism and refusal to acknowledge a viable alternative exemplifies clear bias and unsubstantiated dismissal of Novavax's platform among influential medical commentators.
Negative vaccine outcomes
Myocarditis and related heart inflammation have been reported following mRNA COVID-19 vaccination. On 28 February 2021 the Israeli Ministry of Health notified CDC officials of large reports of myocarditis, particularly in young people, after the Pfizer vaccine. The Permanent Subcommittee on Investigations’ 21 May 2025 majority staff report Failure to Warn records that federal officials were aware of the risk and did not issue a planned Health Alert Network warning.
Economic and Incentive Concerns
This dynamic echoes the 2018 Goldman Sachs analysis questioning whether ‘curing patients’ (or highly effective preventives shrinking the recurring-revenue pool) is sustainable for pharma, a pattern some observers see reflected in the mRNA platform’s faster approvals, larger marketing scale, substantial recurring revenue from boosters (with Pfizer/BioNTech's Comirnaty surpassing $80 billion in cumulative sales and Moderna's Spikevax generating tens of billions), and NIH patent royalties.
The Medicines and Healthcare products Regulatory Agency's authorization of 2 December 2020 was the first for an mRNA product. The trials enrolled 43,548 people (Polack et al., New England Journal of Medicine) and 30,420 (Baden et al., New England Journal of Medicine). Stéphane Bancel said in January 2023 that Moderna made 100,000 doses in 2019, confirmed as the whole pipeline. Nicholas Warne and the other Pfizer authors, Nature Biotechnology, 2 February 2023, report 3 billion Comirnaty doses made in 2021 and more than 3.7 billion distributed through 2022.
Matrix-M, Novavax’s proprietary saponin-based nanoparticle adjuvant, represents a breakthrough platform technology with potential applications far beyond COVID-19 (e.g., future vaccines for other infectious diseases, cancer, etc.), yet this adjuvant innovation was allegedly sidelined along with the COVID vaccine itself.
Alleged Financial Market Disadvantages and Short Selling Pressure
Novavax has maintained persistently high short interest (peaking near 40 % of the float in 2023). As of the September 30, 2026 FINRA short-interest settlement date, reported short interest in NVAX was 46,046,946 shares, down 3,828,264 from 49,875,210 on September 15, 2026, with average daily volume of 5,714,870 and days to cover of 8.06. The company has repeatedly appeared on the SEC Regulation SHO threshold list due to high failure to deliver rates. Observers argue that the persistence of these failures-to-deliver within a small group of prime brokers and market makers reflects network-level dynamics that can delay forced covering. It was also publicly targeted by activist short seller Andrew Left of Citron Research on April 20, 2020, when Citron stated that Novavax was a “serial promise and non deliver” on every virus and expected the stock to return to $15. A February 2026 superseding indictment charged that statement as Count 14. According to the indictment, Left opened a short position in Novavax at approximately 12:28 p.m. that day, including option contracts expiring on April 24, 2020; at approximately 1:16 p.m. he placed a limit order to sell those option contracts at a price approximately equivalent to $19 per share; and he posted the tweet at approximately 1:22 p.m., when his net short exposure was approximately 315,695 shares. The indictment alleged that he began closing the position about one minute later, had closed approximately 94 percent of it within an hour, and had fully closed the position by approximately 10:33 a.m. on April 21, 2020, for a profit of approximately $430,000. On June 1, 2026, a Los Angeles jury convicted Left of one count of securities-fraud scheme and 12 of 16 issuer-specific counts, acquitting him on four; Department of Justice releases did not identify whether the NVAX count was among the convictions. Sentencing originally set for August 31, 2026, was postponed, with post-trial motions remaining pending. The charged conduct concerned trading contrary to publicly indicated positions rather than a finding that the 2020 NVAX commentary was itself false, and the episode predates later periods of elevated short interest.
Market bias allegations further include persistently high short interest in NVAX stock as indicators of market disadvantages.
Retail investors have also published independent analyses of NVAX trading microstructure and convertible bond arbitrage (e.g., an October 2025 X video titled The Bigger Short that gained over 147,000 views, which is based on over 70 million actual trading data points from L1, L2, L3, and NBBO feeds), alleging options pinning, spoofing-like activities, and other price-suppression tactics tied to the persistent high short interest. A Novavax retail investor posting as Camillus de Lellis (@CamillusLellis) published X posts that recorded alleged differential moderation on the Yahoo Finance message board, including a 10 September 2024 post stating that an abusive campaign against Novavax retail investors stayed up while “entirely benign posts supportive of Novavax were censored,” with replies labeled “Censored:” and “Allowed:” and accompanying screenshots. The same account’s 2 September 2024 post opened with the words “Novavax censored vs allowed sampling thread.” An 11 April 2025 thread titled “Attempted Destruction of Novavax Thread” included a reply whose text is “Censoring.”
Yahoo Finance syndicated a recurring StockStory series under the headline “3 Reasons NVAX is Risky and 1 Stock to Buy Instead.” A 20 October 2026 article by Radek Strnad stated that Novavax “struggled to consistently generate demand over the last five years as its sales dropped at a 18.9% annual rate.” A 25 May 2026 article under the same headline and byline had put the five-year sales change at an 8.3% annual decline. Neither article mentioned Novavax’s 10 May 2024 collaboration with Sanofi, under which Novavax was to transfer most commercialization of its COVID-19 vaccine to Sanofi in 2025. Starting in 2025 Sanofi books those product sales; Novavax’s remaining COVID-related economics are royalties, milestones, and supply of vaccine and Matrix-M. The October article treated the 18.9% five-year sales decline as evidence that Novavax “struggled to consistently generate demand,” without distinguishing post-pandemic demand contraction from the accounting effect of Sanofi booking sales after the handoff. Neither article mentioned a $125 million milestone payable when a Sanofi COVID-influenza combination Phase 3 trial starts in the United States or the European Union. The same October 2026 article stated that Novavax’s adjusted operating margin had decreased by 26.9 percentage points over the last two years and that this “shows that costs were rising and it couldn't pass them onto its customers.” Novavax filings reported that costs declined over the period: selling, general and administrative expense was $157 million in 2025, down 53% from $337 million in 2024; cost of sales was $73 million, down from $203 million; and research and development was $342 million, down from $391 million, so that combined research and development plus selling, general and administrative expense fell 31%. In the quarter ended 30 June 2026, selling, general and administrative expense was $27 million, down 39% from a year earlier, and research and development net of partner reimbursement was down 34%. Novavax reported the reductions as the result of Sanofi taking commercialization, the removal of associated commercial staff and infrastructure, and its cost-reduction program. A lower adjusted-operating-margin percentage does not show that those costs rose.
Some independent analysts and specialized short-interest tracking platforms have published estimates of total synthetic short exposure that substantially exceed the official reported short interest levels.
Similar dynamics have been discussed in retail circles regarding major market makers and prime brokers such as Citadel Securities. While Citadel’s disclosed NVAX position is smaller and appears only in routine 13F filings (rather than a passive 13G), observers note the firm’s central role as one of the largest securities lenders and options market makers on the Street. Citadel Securities has faced repeated broader allegations of facilitating short pressure and market manipulation in other high-profile cases; some retail voices view its holdings and lending activity in names like Novavax as part of the same infrastructure that can sustain elevated short interest through borrow facilitation and delta-hedging.
Retail analyses have also focused on the potential impact of convertible note holdings and associated delta-hedging activities. Verified holders of Novavax's convertible notes (instruments that can facilitate convertible arbitrage hedging via stock shorts) include multi-strategy funds such as Point72 Asset Management, L.P., Skaana Management, and Context Capital Management. Retail investors and independent analyses have alleged that Point72 and Skaana have maintained persistent short positions in Novavax over an extended period. Notably, Point72's predecessor firm, SAC Capital, pleaded guilty to insider trading violations in 2013 and paid a record $1.8 billion penalty; however, no specific regulatory findings have linked Point72 to misconduct involving Novavax. These claims remain unverified by regulators. Analyses tied to the 2031 convertible notes have estimated that delta-hedging alone may contribute the equivalent of an additional ~12% of the float in short exposure, with daily rebalancing by convertible holders accounting for 25–50% of average daily volume on volatile days.
Skaana’s short exposure is primarily through put options, consistent with convertible-arbitrage and hedging activity that contributes to sustained short interest. Institutional investors reporting short positions in Novavax via 13F filings (as of March 2026) include Caption Management, Graham Capital Management, Squarepoint Ops, Sculptor Capital, Skaana Management L.P., and others.
Analyst firms such as Bank of America have maintained a consistently bearish stance, citing execution risks, declining COVID-19 vaccine demand, and uncertainties in profitability timelines.
Retail observers note that the same institution disclosed a 5.1% (~8.3 million share) passive stake in February 2026, which they interpret as dealer inventory held to facilitate securities lending to short sellers and convertible-bond hedgers rather than a genuine directional long position. Retail observers interpret this dual role — research coverage alongside securities-lending inventory — as emblematic of how a handful of large players can simultaneously shape both narrative and borrow availability. This dual role has raised questions about potential conflicts of interest between BofA’s research coverage and its market-making / securities-lending activities. Some retail observers have additionally alleged “directional margining” practices by certain prime brokers and clearing firms—i.e., the asymmetric application of margin requirements that purportedly facilitate sustained short positions while imposing stricter capital or availability constraints on long holders. A subset of retail observers extend these allegations to additional large banks such as JP Morgan, framing them as further participants in the alleged network of analyst conflicts and short-facilitation mechanisms.
Retail observers reported that on 16 October 2026 TipRanks published an article presenting the FDA’s 2024 clinical hold on Novavax’s COVID-influenza combination and stand-alone flu candidates as breaking news. That TipRanks article was later taken down. AInvest’s separate article of 16 October 2026, 5:32 p.m. Eastern, “Novavax, Ocular, and QuidelOrtho Fell the Same Day,” stated that Novavax’s roughly 12% drop that day, unlike the declines in Ocular Therapeutix and QuidelOrtho, had a genuine catalyst in that same hold. The FDA had already removed the hold nearly two years earlier, on 11 November 2024, after concluding the reported serious adverse event was unrelated to vaccination.
Alleged Impact on Share Price, Corporate Actions and Vaccine Availability
Critics contend that the stricter regulatory scrutiny, delayed approvals, thinner procurement, pharmacy-level distribution obstacles, and short-selling pressure alleged above drove Novavax’s share price down from its February 2021 high of $319.93. The resulting weaker price made subsequent share issuances more dilutive: shares outstanding rose from about 78 million at year-end 2022 to 162.9 million as of 16 February 2026, and in August 2025 the company issued $225 million of 4.625 percent convertible senior notes due 2031, largely in exchange for existing 2027 notes plus about $50 million of new cash. Critics have argued that the larger float and convertible-related hedging, together with the Bank of America stake discussed above, increased stock available to borrow and thereby compounded downward pressure, so that further cash raised more dilution. After the February 2023 warning of substantial doubt about continuing as a going concern, with cash not expected to last past early 2024—an announcement accompanied by an approximately 25 percent share-price drop— the company implemented a May 2023 reduction of about 25 percent of its workforce, a January 2024 reduction of about 12 percent, later staff and facility cuts, the December 2024 sale of the Bohumil manufacturing plant, and an October 2025 transfer of a U.S. facility as part of site consolidation. Critics argue that these reductions removed commercial staff and plants and that subsequent filings then cited low uptake as a reason for further cost cuts. Product sales, while Novavax remained the seller, contributed to total revenue falling from $1.98 billion in 2022 to $682 million in 2024. The 10 May 2024 co-exclusive license agreement with Sanofi left 2025 COVID-19 vaccine sales and distribution with Sanofi; after marketing-authorization transfers completed in October 2025 (European Union) and on 4 November 2025 (United States), Sanofi held those authorizations. Royalties and remaining milestones depend on Sanofi’s volumes, and Novavax no longer controls pharmacy access or orders in those markets. Critics argue that a small Sanofi season leaves the equity valued largely as a royalty stub, which they say keeps the next financing dilutive. Critics contend that the scrutiny, delayed approvals, thinner procurement, pharmacy-level obstacles, short-selling, dilutive financing, workforce and plant reductions, and loss of control over orders amplified one another and together impaired Nuvaxovid availability.
Absence of Major Investigations
These allegations draw from public interviews, congressional and parliamentary testimonies, regulatory meeting records, official approval timelines, patent royalty information, procurement documents, SEC filings, and financial reports. Despite the allegations of political influence, unequal regulatory scrutiny, procurement bias, market manipulation claims, and testimonies by figures such as former CDC Director Robert Redfield and German witnesses including Sterz, no major investigations have been launched into these matters.
Health/vaccine regulatory agencies (FDA/EMA and approval/safety scrutiny)
Critics have also pointed to the multi-hour September 18–19, 2025 ACIP meeting (under the RFK Jr. administration) where presenters extensively discussed mRNA-specific issues such as ribosomal frameshifting and persistent spike protein production, yet no comparisons were made to Novavax — the only other fully approved COVID-19 vaccine platform at the time.
Parliamentary/political oversight bodies (German Enquete-Kommission and prior commissions)
-
The German Bundestag Enquete-Kommission has heard testimony critical of mRNA safety testing and procurement (including from Sterz, Spahn, and others), but has not mentioned Novavax at all, maintaining total silence on the company or its Matrix-M adjuvant technology.
-
No other German Enquete-Kommission or Untersuchungsausschuss (at federal or state level) has ever mentioned or examined Novavax, its protein-subunit platform, or its Matrix-M adjuvant technology in any proceedings, reports, or hearings.
Critics view this absence of official scrutiny as further evidence that the alleged biases remain unaddressed at the institutional level. Observers have also noted that these circles frequently overlap with influential global-health and philanthropy networks that shaped the pandemic response.
Circle-like Networks Narrative
Some observers synthesize the "circle-like networks" narrative as a chain of events involving lab-adjacent gain-of-function research and biosecurity pre-positioning—through programs such as DARPA's ADEPT/P3, Metabiota (funded by In-Q-Tel), and various German research institutes—leading to a pandemic reaction in which the mRNA “solution” was allegedly protected at every level. Observers further allege that these overlapping elite networks extend into the biosecurity and pandemic preparedness apparatus. This includes connections to entities such as Metabiota (which received funding from In-Q-Tel, the CIA's venture capital arm), Munich Re's pandemic risk modeling initiatives, and German research institutions with historical virus work such as the German Cancer Research Center (DKFZ) and the Friedrich-Loeffler-Institut on Riems island.
Metabiota agreements, the Global Virome Project, and PREDICT
On 1 February 2016 Munich Re entered a long-term cooperation agreement with Metabiota, founded by Nathan Wolfe. On 22 August 2017 Munich Re and In-Q-Tel each signed a strategic agreement with Metabiota, announced the same day; Munich Re personnel quoted in related announcements included Tom van den Brulle and Gunther Kraut.
On 23 February 2018, Science published a Policy Forum article, volume 359, pages 872–874, “The Global Virome Project” (doi:10.1126/science.aap7463). Peter Daszak of EcoHealth Alliance is the corresponding author. Nathan D. Wolfe is a coauthor, with Dennis Carroll, George F. Gao, Carlos M. Morel, Subhash Morzaria, Ariel Pablos-Méndez, Oyewale Tomori, and Jonna A. K. Mazet. The paper describes a project aimed to launch in 2018 to identify unknown mammal and bird viruses and supply that data for public-health interventions.
Observers in this narrative note that Wolfe is already the Metabiota founder on the Munich Re agreement, and that Daszak is EcoHealth Alliance’s president and was later the only American on the WHO joint study team that rated a laboratory incident “extremely unlikely”; they treat this paper as the 2018 document those two figures share.
They further note USAID’s PREDICT program as an earlier shared vehicle: EcoHealth Alliance’s 21 November 2014 announcement of the second phase named the consortium that executed it as the UC Davis One Health Institute, principal investigator Jonna Mazet; EcoHealth Alliance; Metabiota; the Smithsonian Institution; and the Wildlife Conservation Society. Dennis Carroll, director of USAID’s emerging threats division, designed and oversaw the program; USAID held the award.
In April 2020 emails released from UC Davis and published by U.S. Right to Know, Daszak told that consortium, including Metabiota, to keep certain China sequences out of the PREDICT GenBank release because they belonged to the NIH grant just terminated. Some observers link these to global-health pre-positioning efforts.
DARPA RNA pre-positioning
They frame this as part of a "PRS loop" (Problem-Reaction-Solution dynamic): allegedly using gain-of-function-adjacent research, surveillance programs, and pre-positioned mRNA-based "medical countermeasures" to create or amplify pandemic threats via lab and intelligence networks, then promoting the mRNA "solution" as the primary response while financially, regulatorily, and through media/procurement channels kneecapping superior alternative platforms like Novavax's recombinant protein-subunit vaccine with Matrix-M adjuvant. These same networks had pre-positioned mRNA technology years earlier through DARPA’s ADEPT/P3 programs and related biosecurity initiatives, creating the structural imperative to protect the chosen platform while sidelining recombinant-protein alternatives like Novavax.
Dan Wattendorf was the DARPA program manager behind the RNA work and joined the Gates Foundation in 2016.
Observers point to these connections as further evidence of overlapping networks in finance, global health, and European elite circles that may have influenced perceptions and policy around vaccine platforms during the pandemic.
Gates commitment to Valera
On 12 January 2016 the foundation committed up to $20 million to Moderna’s infectious-disease unit, Valera, for an mRNA antibody combination against HIV, with a possible expansion to $100 million for further infectious-disease projects.
Flagship’s Moderna stake and the Berenson seat
Observers in this narrative also note that Flagship Pioneering founded Moderna in 2010. Noubar Afeyan, Flagship’s founder and chief executive, has served as Moderna’s chairman. Moderna’s 2018 IPO prospectus lists the same 58,882,696 shares (19.5 percent before the offering and 17.9 percent after it) as beneficially owned by both Afeyan and Flagship Pioneering and affiliated entities. Those shares were held in Flagship funds of which Afeyan and Edwin M. Kania, Jr. were the managers of the general partner.
Stephen Berenson spent 33 years at J.P. Morgan, the last twelve as vice chairman of investment banking through April 2017. He joined Flagship Pioneering in June 2017 as a managing partner and became a Moderna director that year. Moderna’s 2023 proxy lists him as chair of the compensation committee. He left that board in August 2024, prior to the 2025 proxy.
Blackstone influenza funding
Observers in this narrative also note that on 27 March 2024, funds managed by Blackstone Life Sciences agreed to provide up to $750 million for Moderna’s investigational mRNA influenza program. Moderna keeps full rights and control and records the money as a reduction in research and development expense. Moderna’s 2025 Form 10-K says the payback is contingent on a U.S. approval that depends on data from the funded work. If that condition is met, Blackstone is entitled to low-single-digit royalties and up to $750 million in sales milestones on net sales of future influenza and flu-combination vaccines. The royalty does not cover Spikevax, mNEXSPIKE, mRESVIA, or the Merck cancer vaccine. Moderna’s filings show research-and-development reductions of $267 million in 2024, $340 million in 2025, and $74 million in the first half of 2026, against the $750 million cap. The Phase 3 trial of mRNA-1010 was funded by Blackstone Life Sciences and Moderna.
On 5 August 2026 the FDA approved that vaccine as mFLUSIVA for adults 50 and older: a standard approval for ages 50 to 64, and an accelerated approval for ages 65 and older. The last Moderna quarterly report found before that approval still describes the royalty as contingent, so a booked royalty payable is not in that filing.
NIH agreement with the Office of the Assistant Secretary of War
Observers in this narrative also note that an earlier Department of War document is a different instrument. On 4 and 5 August 2026, Robert Kadlec, Assistant Secretary of War for Nuclear Deterrence, Chemical, and Biological Defense Policy and Programs, and NIH Director Jay Bhattacharya signed an interagency agreement under which NIH may transfer funds to the Office of the Assistant Secretary of War for medical countermeasures against pandemic influenza, chemical, biological, radiological, and nuclear threats, and emerging infectious diseases. The agreement states no dollar amount and names no grantee. It runs to 2036. Kadlec previously served as HHS Assistant Secretary for Preparedness and Response during Operation Warp Speed.
DTRA award to Flagship
The 23 September award, up to $47 million over five years to Flagship Health Security Corporation through DTRA’s Joint Science and Technology Office, is a separate action, and its announcement does not identify Moderna as a funded project.
Observers in this narrative also note that on 23 September 2026 the Department of War awarded Flagship Pioneering a first-of-its-kind contract of up to $47 million over five years under the ONTARGET (Operationalizing Novel Technologies for Advanced Rapid Generation of Effective Medical Countermeasures) program, managed by the Joint Science and Technology Office of the Chemical and Biological Defense Program at the Defense Threat Reduction Agency, under Robert Kristovich.
The award is administered by Flagship Health Security Corporation, a subsidiary created for government work, and supplies proof-of-concept funding for initial projects at Flagship-founded companies Apriori Bio (Octavia platform for variant-resilient countermeasures) and Prologue Medicines (DELVE platform for mining viral proteins for immune modulation), with the option to add further projects during the term.
Flagship’s announcement lists Moderna among its ecosystem of more than 40 companies but does not identify Moderna as a funded project.
German special program of 15 September 2020
On 15 September 2020, Health Minister Jens Spahn and Research Minister Anja Karliczek, both CDU, announced a special program providing up to €750 million to three German vaccine developers. The Bundestag funding table shows BioNTech received €375,002,291, approved 9 September 2020 and backdated to 1 February 2020. The third recipient was IDT Biologika, at €113.7 million. Novavax was not on the list.
Commission buying shift and the bilateral BioNTech doses
A Bundestag paper says press reports describe a June 2020 letter from Spahn to von der Leyen, after a push by Merkel, moving vaccine buying from the Germany–France–Italy–Netherlands alliance to the Commission.
In September 2020 Spahn’s ministry also signed a bilateral preliminary contract for 30 million BioNTech doses on top of Germany’s EU share. His spokesman said in January 2021 that a later EU order did not replace that contract, and that the extra German doses would be delivered after other states’ earlier orders. On 22 January 2021 Sabine Weiss, the CDU parliamentary state secretary, told the Bundestag that BioNTech/Pfizer had still made no firm promise to deliver the extra 30 million. Spahn said Germany had approached BioNTech and CureVac only after the EU procedures were finished.
On 7 January 2021 Spahn himself said Germany had secured 90 million BioNTech doses and 50 million Moderna doses for the year.
CEPI award and the 1 February 2020 call
On 23 January 2020 the Coalition for Epidemic Preparedness Innovations, which Wellcome co-founded, funded Moderna’s coronavirus vaccine. Jeremy Farrar was running Wellcome and convened the 1 February call nine days later.
On 1 February 2020, Jeremy Farrar of the Wellcome Trust convened a confidential call and wrote that his preference was to keep it “a really tight group.” The invite list included Anthony Fauci, Kristian Andersen, Robert Garry, Edward Holmes, Andrew Rambaut, Christian Drosten, Ron Fouchier, Marion Koopmans, Stefan Pöhlmann, Patrick Vallance, and Paul Schreier. Francis Collins and Lawrence Tabak joined as well. Fauci brought Collins onto the call.
The day before the call, Andersen wrote to Fauci that some of the features of the genome “(potentially) look engineered” and that he and colleagues “all find the genome inconsistent with expectations from evolutionary theory.”
On 2 February 2020, Collins wrote that the arguments from Fouchier and Drosten were “presented with more forcefulness than necessary,” that he was “coming around to the view that a natural origin is more likely,” and that otherwise “the voices of conspiracy will quickly dominate, doing great potential harm to science and international harmony.”
Drosten, of Charité in Berlin, Fouchier and Koopmans, of Erasmus in Rotterdam, and Pöhlmann, of the German Primate Center, are the European scientists who actually sat with Fauci.
WHO joint study
Farrar, who organized the call, later became the World Health Organization’s chief scientist. Koopmans was also a member of the World Health Organization's joint study team that visited Wuhan in January and February 2021. Peter Daszak, president of EcoHealth Alliance (which held the U.S. NIH grant that included a subcontract to the Wuhan Institute of Virology), was the only American on the international team. The joint report rated a laboratory incident "extremely unlikely."
McManus and the BARDA comparison
This purported protection included board gatekeepers like Michael A. McManus Jr. (long-time Novavax director with prior Pfizer and Reagan-era White House ties), finance-media influence via Apollo Global Management's ownership of Yahoo (including Yahoo Finance), regulatory capture, short-side pressure, and procurement priorities—while Novavax's non-spike-protein recombinant protein-subunit vaccine with Matrix-M adjuvant was deliberately delayed and sidelined.
Novavax received the same ~$1.6 billion BARDA/Operation Warp Speed lifeline as the mRNA programs — yet its manufacturing remediation was paused, international partners delayed, and regulatory clock ran 18+ months longer.
Observers in this lens argue the funding was never intended to create a true rival platform; it was risk-mitigation theater while mRNA (Gates’ September 2019 BioNTech bet + German-origin tech) received the real at-risk scaling, media amplification, and procurement priority. Even figures with deep military/intel-adjacent backgrounds (e.g., long-time Novavax board member Michael A. McManus Jr. (Reagan White House Deputy Assistant to the President + ex-Pfizer corporate counsel, on Novavax board since 1998)—a 20+ year insider with ties to elite political and pharmaceutical establishments, serving as a potential permanent gatekeeper) could not break the pattern. This demonstrates elite embedding at the corporate level long before the pandemic, ensuring no real threat to the chosen mRNA platform. The network protected the chosen platform, not “vaccine innovation.”
Finance-circle records through the Epstein limit comparison
Retail observers further note that the named institutions and funds operate within a relatively small, tightly interconnected elite circle of Wall Street prime brokers, market makers, and multi-strategy funds. Public court records have illustrated how tightly interconnected these finance circles can be, including documented associations involving principals or entities linked to some of the named players.
Along with Steve Cohen/Point72 (which has file mentions and a photo from recent Epstein document releases, though Point72 has issued a strong denial of any personal relationship or meetings),
Leon Black/Apollo Global Management (Apollo Global Management acquired Yahoo, including Yahoo Finance, from Verizon in 2021, which has served as a major news source for Novavax and COVID-related information as well as a key platform for public investor discussions on the company, amid allegations of content moderation bias),
Bank of America, and JPMorgan—which have extensive, well-documented public-record overlaps including payments, settlements with Epstein victims, and lawsuits—that all have played a role in the Novavax story, this illustrates how small and overlapping certain elite circles in finance and pandemic preparedness can be.
Bill Gates, whose foundation invested $55 million in BioNTech in September 2019 and who became one of the most visible public advocates for mRNA COVID-19 vaccines, held multiple documented meetings with Jeffrey Epstein after Epstein’s conviction to discuss global-health initiatives.
Department of Justice Epstein files also include emails from Nathan Wolfe to Epstein. Inside Higher Ed on 5 February 2026 dated the emails from 2008 to 2013. In file EFTA00961409, Wolfe asked whether funding for a study he said he had co-created was a go. Wolfe told Inside Higher Ed the study was never pursued.
The New York Times on 12 October 2019 described a photograph taken on 3 May 2011 in the entrance hall of Epstein's Manhattan mansion showing James E. Staley, then a senior JPMorgan executive; Lawrence Summers; Jeffrey Epstein; Bill Gates; and Boris Nikolic, science adviser to the Gates Foundation. The Times reported that the foundation and JPMorgan were then building the Global Health Investment Fund, and that Staley told colleagues Epstein wanted to be brought into those talks.
LHGP Asset Management, Lion’s Head, in London, was engaged to originate and exit the investments. The Gates Foundation and the Swedish International Development Cooperation Agency agreed to offset up to 60 percent of losses. Anchor support came from Grand Challenges Canada, the German Ministry for Economic Cooperation and Development through KfW, and the Children’s Investment Fund Foundation. Jamie Dimon spoke for the bank.
The manager’s portfolio page lists twelve companies: Access Bio, Alydia Health, Atomo Diagnostics, BD, EUBiologics, Genedrive, IanTech, Medicines Development for moxidectin, PATH, Serum Institute of India, Themis Bioscience, and Univercells. Serum Institute’s line on that page is snakebite anti-venom, Tdap in pregnancy, and tuberculosis.
On 16 August 2011, Epstein wrote to Staley and Mary Erdoes, head of JPMorgan asset and wealth management, that a separate fund would give Gates access to people, investment, allocation, and governance without upsetting his marriage or the foundation's staff; Epstein was proposing a fee for himself.
These observations do not suggest any direct Epstein-network coordination or involvement in Novavax matters.
SEC and FINRA
These tightly interconnected elite finance circles maintain strong, ongoing connections to the SEC and FINRA through the revolving door, extensive lobbying, and direct regulatory oversight as major prime brokers, market makers, and hedge funds. Bank of America, as a leading securities lender and broker-dealer, operates under constant SEC and FINRA supervision while participating in NVAX-related short interest and analyst coverage. Steve Cohen/Point72 has a long history of high-profile SEC enforcement interactions (including the 2013–2016 insider-trading resolution) and continues to function as a regulated entity within the same Wall Street network.
Specifically, no formal SEC or FINRA enforcement actions or investigations have been publicly disclosed targeting the named institutions, funds, prime brokers, or market makers for alleged coordinated trading, short-selling practices, or systemic disadvantages to Novavax. U.S. agencies including the SEC and FBI have also not initiated formal probes into potential regulatory favoritism toward mRNA platforms.
This regulatory-financial nexus is especially relevant to Novavax’s market dynamics because SEC and FINRA rules (such as Regulation SHO exemptions for bona-fide market making and securities-lending oversight) directly shape the short-selling pressures and borrow availability the section already describes.
These claims remain unsubstantiated by official investigations and are presented here as part of the ongoing retail-investor and independent-observer narrative.
Henry Jarecki
Epstein’s longtime BFF Henry Jarecki (German-born psychiatrist, Yale professor, commodities trader and billionaire with private islands in the BVI) was not just “close friends” — he flew on the Lolita Express, exchanged emails with Epstein about disguises/plastic surgery to “avoid getting caught,” and was named in the public Epstein files (including his note in Epstein’s birthday book).
Jarecki’s deep Heidelberg University roots and connections to the Heidelberg Club International (HCI) network create the direct bridge between the already-mentioned Wall Street players (Point72/Steve Cohen file mentions, Leon Black/Apollo, BofA and JPMorgan Epstein settlements) and specific families and entities within the German elite/pharma ecosystem—including Octapharma/Wolfgang Marguerre, Reimann-Dubbers/Reimann Investors, and CSL Behring plasma networks—that have dominated European blood-products, vaccine-adjuvant, and pandemic-procurement circles for decades.
This same tight circle helped shape pandemic policy — exactly the “influential global-health and philanthropy networks” the current section already flags with Gates’ September 2019 BioNTech investment and post-conviction Epstein meetings.
Within the German CDU political establishment that forms part of this circle, Ursula von der Leyen — a prominent CDU insider who, together with her husband Heiko, was photographed socializing with the zu Guttenberg family at the 2009 ‘Innocence in Danger’ reception in Berlin — is positioned in the same German-elite context as Karl-Theodor zu Guttenberg, Stephanie zu Guttenberg, Angela Merkel’s 2019 Wuhan visit, and ‘pandemic preparedness’ timelines.
As President of the European Commission during the COVID-19 pandemic, she played a decisive role in driving and prioritizing the EU’s massive Pfizer-BioNTech mRNA vaccine procurement, significantly elevating the German-developed mRNA platform to continent-wide dominance.
Alena Buyx
Alena Buyx, former chair of the German Ethics Council during the mRNA rollout, participated in a panel discussion at the Heidelberger Frühling festival in March 2026 — an event supported by Günter Reimann-Dubbers of the Reimann family and embedded in the same Heidelberg philanthropic circles that include Henry Jarecki. Observers note that this participation highlights additional interconnections within the Heidelberg-based philanthropic and elite networks discussed in this narrative, particularly given Reimann-Dubbers' and Jarecki's shared status as Honorary Senators of Heidelberg University and their overlapping philanthropic activities in the region.
Karl Lauterbach
Karl Lauterbach, as Federal Minister of Health since December 2021, played a central role in Germany’s overall pandemic response. As the senior health minister he personally directed vaccine procurement strategy, public policy, and rollout during the main vaccination and booster phases. Germany ordered massive volumes of BioNTech/Pfizer mRNA vaccines while the EMA-approved Novavax protein-subunit vaccine (Nuvaxovid) received only marginal orders and almost no promotion.
On Bild TV’s “Die richtigen Fragen” on the evening of 19 December 2021, Lauterbach stated that Novavax would not be “ein Game Changer” and that the Moderna and BioNTech vaccines already given millions of times were, according to the studies, “eine ganze Spur sicherer.”
On 3 March 2022, at a Kassenärztliche Bundesvereinigung discussion, with about 13,200 Nuvaxovid first doses recorded by the Robert Koch Institute, he said the product could “nicht wirklich erfolgreich” be used, that a “Verhetzung” against it online was far enough along that it was not really placeable, and that the only way to get much further was a general vaccine mandate.
Health Minister Karl Lauterbach completed his doctoral studies under Nobel laureate Amartya Sen and has publicly documented meetings with Sen and Sen’s wife Emma Rothschild.
Lothar Wieler
Critics allege that political connections and decisions detailed in the Circle-like Networks Narrative section contributed to disparities in regulatory scrutiny and procurement favoring mRNA vaccines over alternatives like Novavax at the EMA level.
Critics also point to Germany's Robert Koch Institute (RKI), the federal public health agency responsible for disease surveillance and policy recommendations during the pandemic. Under Lothar Wieler, who served as RKI president from 2015 until his resignation in April 2023, the institute's guidance and risk assessments are alleged by critics to have prioritized mRNA vaccines (such as BioNTech/Pfizer and Moderna) while contributing to delays or lesser emphasis on alternatives like Novavax's protein-subunit vaccine.
Following his departure from RKI, Wieler took up the position of Chair of Digital Global Public Health and Coordinator of the Digital Health Cluster at the Hasso Plattner Institute (HPI) for Digital Engineering at the University of Potsdam—an institution founded and substantially funded by SAP co-founder Hasso Plattner.
On 31 January 2023 HPI announced that he would become spokesperson of the Digital Health Cluster from 1 April 2023, after the Hasso Plattner Foundation decided to expand the institute’s digital-health work.
His HPI biography also lists him as a member of the World Health Organization’s Strategic and Technical Advisory Group on Infectious Hazards (STAG-IH).)
This career transition exemplifies the revolving-door pattern between public health regulatory bodies and private digital-health/technology ecosystems within German elite and business networks, aligning with the broader allegations of structural favoritism toward mRNA platforms.
Dietmar Hopp and CureVac
Observers in this narrative also highlight Dietmar Hopp, the other SAP co-founder, whose firm dievini Hopp BioTech holding GmbH & Co. KG had owned approximately 80 percent of CureVac (a German mRNA developer) since 2005. On 15 June 2020, Hopp and Economy Minister Peter Altmaier announced that the state bank KfW would invest €300 million for about 23 percent of CureVac. A shareholders’ agreement dated 16 June 2020 put KfW and Hopp’s vehicles in shared control of a majority of the shares, with voting rights on specified matters exercised on the federal government’s instructions. The same government program later granted CureVac €251.6 million (notified in early September 2020).
Vaccine Company seats
Observers in this narrative also note that Anthony Fauci’s curriculum vitae lists him from 2023 as a member of the Scientific Advisory Group of Vaccine Company, Inc.
Its chief medical officer is Julie Ledgerwood, previously chief medical officer of the Vaccine Research Center at NIAID (the center was established by presidential executive order in 1997 and opened in 2000 at NIAID, the institute Fauci directed from 1984 through 2022), who oversaw the NIH site of Moderna’s first COVID-19 trial. The Vaccine Research Center and Moderna finalized the mRNA-1273 sequence on 13 January 2020, and the first participants were vaccinated on 16 March 2020. Julie E. Ledgerwood is a coauthor of the 14 July 2020 New England Journal of Medicine report of that trial; Lisa A. Jackson is the first author. Moderna’s 16 March 2020 release stated that the NIH ran the study under its own Investigational New Drug application.
Its chief financial officer, Sonya Bernstein, served as a senior policy adviser on Jeff Zients’s White House COVID-19 team and played a leading role in designing and implementing the administration’s program enlisting more than 40,000 pharmacies to receive and administer vaccines and standing up more than 900 federally supported vaccination sites with FEMA.
Its chief executive, Susan Silbermann, had chaired Pfizer’s global COVID-19 task force; IAVI described it as the internal body she created for colleague safety and business continuity, and Mallinckrodt’s 5 October 2022 announcement stated that as chair she developed and led an organization-wide task force overseeing the safety and well-being of 100,000 colleagues in more than 100 countries. The same announcement listed her as president of Pfizer Vaccines from 2012 to 2018 and global president of Emerging Markets from 2018 to 2020, including the initial supply of COVID-19 vaccines in those regions.
She has served on the Gavi board (2017–2020) and the IAVI board.
Lilly acquisition and Intercept
Intercept’s head of science, Devin Sok, was vice president of discovery at IAVI.
On 26 May 2026 Eli Lilly agreed to acquire the company for up to $1.55 billion.
Seven months earlier Lilly had hired former FDA official Peter Marks to lead its infectious-disease research.
Marks and Nisha Nanda of Lilly serve as advisors to Intercept, a $500 million philanthropic initiative launched on 24 June 2026 for broad-spectrum preventatives and air cleaning, whose co-head Charlie Petty previously invested in Vaccine Company.
Intercept’s advisors also include Moncef Slaoui, a Moderna director from July 2017 until 15 May 2020 and then Operation Warp Speed’s chief scientific adviser after being interviewed by White House officials including senior adviser Jared Kushner and coronavirus coordinator Deborah Birx. Kushner served on the Operation Warp Speed board of directors along with HHS Secretary Alex Azar, Defense Secretary Mark Esper, and Adam Boehler. Slaoui has said he met with Kushner before accepting the position and asked whether the work would be politically interfered with.
Darin Edwards appeared on Intercept’s August 2025 symposium list and was Moderna’s mRNA-1283 program leader at the 20 November 2025 analyst day.
They frame these overlapping personnel, funding, and acquisition events as further evidence of networks that staffed, funded, and later absorbed a startup advised by Fauci while the same FDA official cited in Novavax purity-standard allegations moved to the acquiring company.
ARPA-H award
On 25 September 2024 ARPA-H awarded Vaccine Company up to $49 million for flavivirus vaccines, with $28,179,321 obligated, naming Ledgerwood principal investigator.
BND Project Saaremaa
German intelligence (BND Project Saaremaa under President Bruno Kahl) assessed in early 2020 a probability of a lab-origin accident at Wuhan reported as 80–95 percent by Die Zeit and Süddeutsche Zeitung and 80–90 percent by the BBC, personally briefed Angela Merkel's chancellery, and kept the assessment classified; reporting indicates it was not given to the World Health Organization or the German Corona expert council, with findings shared with the CIA in autumn 2024. A later Deutsche Apotheker Zeitung account described the BND's contemporaneous probability as 50–80 percent.
ATHOS gift to the CDU
Observers in this narrative also note that the CDU’s 2024 party accounts list ATHOS KG, Bergfeldstraße 9, Holzkirchen, for €170,000. Abgeordnetenwatch identifies that firm as the Strüngmann family office and dates the gift to 29 November 2024, its first published large donation to a party.
BioNTech ownership
In 2020, AT Impf GmbH held 47.37 percent of shares (50.33 percent at year-end 2019), conferring de facto voting control..pdf) BioNTech’s 2025 annual report shows AT Impf still holding 40.3 percent as of 31 December 2025. Helmut Jeggle, a general partner of ATHOS, has served as the family’s representative and chairman of BioNTech’s supervisory board since 2008. The Bill & Melinda Gates Foundation’s $55 million 2019 equity investment was a later minority stake, while the German family office retained control of the company whose vaccine the European Commission later procured at large scale.
Business Strategy and Leadership Critiques
Throughout much of the COVID-19 pandemic and its aftermath, Novavax experienced persistently elevated short interest, reflecting investor skepticism about the company's ability to successfully commercialize its vaccine candidate and achieve sustained profitability. Short interest peaked above 40% of the float in multiple periods (e.g., 42–51% in 2023) and remained high at approximately 33% of the float (52.59 million shares short) as of December 15, 2025, continuing to make NVAX one of the more heavily shorted biotechnology stocks. This elevated short interest resulted in Novavax being placed on the SEC's Regulation SHO Threshold list during certain periods, such as in March 2023, due to significant fails-to-deliver positions.
In January 2025, Novavax announced a corporate growth strategy shifting from developing and commercializing its COVID-19 vaccine to research and development and partnerships around its technology platform, including Matrix-M, with Sanofi to lead COVID-19 vaccine commercialization beginning that year. At the Bank of America Global Healthcare Conference on May 13, 2026, a Bank of America analyst described the company as having executed a pivot from a vertically integrated COVID-vaccine company to a technology platform business built around partnering Matrix-M; CEO John Jacobs said the strategy had been launched in January 2025.
Novavax's business strategy has faced scrutiny for its heavy reliance on COVID-19 vaccine revenues, which peaked at $1.98 billion in 2022 but declined sharply thereafter due to market saturation by mRNA competitors and delayed commercialization efforts, leading to missed market-share capture. Analyst firms such as Bank of America have maintained a consistently bearish stance, citing execution risks, declining COVID-19 vaccine demand, and uncertainties in profitability timelines. This approach exacerbated financial strain, prompting multiple restructurings, including a 25% workforce reduction in 2023 and site consolidations in 2025 that yielded $60 million in payments but underscored ongoing cost inefficiencies.
Leadership under former CEO Stanley Erck, who served from 2011 to 2023, drew criticism for delays in scaling production and securing regulatory approvals during the pandemic, which allowed rivals like Pfizer and Moderna to dominate the market before Novavax's vaccine reached significant distribution in mid-2022.
The company's board cited a need for a "fresh perspective" in replacing Erck with John Jacobs in January 2023, amid broader failures in vision and communication.
Erck's tenure also involved executive stock sales totaling $46 million in 2020 amid rising share prices from vaccine trial optimism, prompting a 2022 investor lawsuit alleging insider trading based on non-public information about trial setbacks.
Under Jacobs, efforts to pivot toward R&D partnerships have aimed for financial discipline, yet analysts critique weak commercial execution.
The March 4, 2025 corporate presentation (Exhibit 99.1 to SEC accession 0001104659-25-020023) listed “Investor day in 2H 2025” among items investors should track that year, alongside Sanofi milestones and the mid-year CIC and flu cohort; the associated revenue framework was dated February 27, 2025. At the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025, John Jacobs said the company was planning an investor day in the second half of the year to report on the early-stage pipeline. On the August 6, 2025 earnings call, Ruxandra Draghia-Akli said she was looking forward to hosting the investor day in the coming quarters and going into those programs in greater detail. The investor-relations events page, through the September 10, 2026 Citi conference, listed earnings calls and outside conferences but no investor day.
As of March 2026, Novavax management under CEO John C. Jacobs has not issued any public statements or taken visible company-led actions specifically addressing the company's persistently high short interest. Nor has current or former leadership (Erck or Jacobs) made any documented public response, rebuttal, investor presentation, or legal action to counter the broader allegations of systemic government and regulatory favoritism toward mRNA platforms, unequal scrutiny, procurement bias, or suppression of Novavax’s scientific advantages that are detailed in the preceding section.
Critics argue this silence has allowed the narrative of bias to persist without pushback from the company, further eroding investor confidence and contributing to sustained short interest and share-price pressure.
These pressures reflect causal links between early strategic delays—such as manufacturing bottlenecks—and enduring leadership challenges in adapting to post-pandemic vaccine dynamics, where one-off government contracts failed to translate into commercial viability.
On October 13, 2025, Shah Capital (then a 7.2 % holder of 11.8 million shares) sent a letter from managing partner Himanshu Shah to Novavax’s board, filed as Exhibit 99.1 to Schedule 13D/A (accession 0001398344-25-019099). The letter cited approximately 7 000 doses versus about 6 million by mRNA competitors as of 2 October, short interest of about 25 % versus a 9 % average as of 15 September, and called for an immediate formal strategic review for a potential sale.
In a second letter dated 12 November 2025 (Exhibit 99.1 to accession 0001398344-25-020786), Shah Capital, then holding an 8.3 % stake as the second-largest shareholder, criticized weak commercial execution by Novavax and partner Sanofi, stating that “it is reasonable to question whether Novavax and its partner are exhibiting a profound lack of competence or intentionally underperforming,” and noting approximately 120 000 doses versus 14.5 million as of 31 October (0.8 % share), share count more than doubled since September 2022, misleading non-dilution claims, and a $29 million Q3 charge for untimely convertible refinancing. The letter urged formation of a committee to evaluate a sale and hiring of an investment bank. In a same-day Reuters interview Shah described the November letter as the second in a month and warned of a potential proxy fight if no meaningful progress occurred within four months.
On April 8, 2026, Shah Capital, then a 9% shareholder, sent an open letter to the Novavax board notifying it of the firm's intention to vote against the re-election of board nominees and against the executive compensation package at the 2026 annual meeting. The letter cited value destruction from January 1, 2023, to March 31, 2026, with the share price falling from $11 to $8, shares outstanding rising from 83 million to 163 million, and cash and equivalents declining from $1.35 billion to $750 million as of December 31, 2025. It described approximately $22 million in 2025 Nuvaxovid revenue, representing roughly a 1% market share, as unacceptable, and called for a 30% reduction in the senior management team and a reduction of the board from eight directors to five. Himanshu Shah told Reuters that "My letter is an indictment of the leadership" and stated that the firm would not launch a proxy fight against an entrenched eight-member board.
On April 28, 2026, Dana Parish interviewed Himanshu Shah of Shah Capital in Raleigh. Shah stated that the firm began buying Novavax shares in late 2022 after they had fallen from about $250 to about $10 and that the stake was then about 9 to 10 percent. He said the commercial operation had failed completely and that a vaccine with those advantages should have held 50 to 60 percent of the market rather than about 1 percent. Shah Capital's letters and the interview did not address stock manipulation or corporate sabotage, instead explaining the record as management execution failure in marketing, dilution, fiduciary duty, and a commercial share of about 1 percent against the 50 to 60 percent potential he named.
At the June 18, 2026, annual meeting, stockholders re-elected John C. Jacobs, Gregg H. Alton, and Richard J. Rodgers as Class I directors. The advisory vote on executive compensation passed 35,779,461 to 34,858,658. On June 24, Shah Capital stated that nearly half of votes cast opposed the pay package and that approximately 38 to 41 percent of votes were cast against each of the three directors, describing the result as a wake-up call for leadership.
The April 27, 2026, proxy statement detailed the Compensation Committee's evaluation of 2025 performance. Chaired by David Mott with members Rachel King, Richard J. Rodgers, and John Shiver, the committee scored the "Advance Sanofi Partnership" objective (30 percent weighting of the cash bonus) as fully met, citing $225 million in milestones from U.S. BLA approval and marketing authorization transfers. Overall corporate achievement was assessed at 93 percent, with two additional points of discretion applied for unforeseen challenges, yielding a 95 percent payout. Mott, who became Chairman of the Board in 2026, previously served as President, Chief Executive Officer, and Vice Chairman of MedImmune from 2000 to 2008 and led its sale to AstraZeneca in June 2007 for $15.6 billion. The proxy highlighted 2025 agreements with AstraZeneca to transfer one U.S. facility and sell equipment for $60 million. Class II director Margaret G. McGlynn, whose term runs to 2027, is the former President of Merck Vaccines and Infectious Diseases.
On May 14, 2026, Shah Capital sent a presentation to the board that was filed the next day as an exhibit to Schedule 13D/A (accession 0001398344-26-009210). It described the Sanofi partnership as underwhelming because Nuvaxovid was not promoted in the 2025–26 season.
On October 16, 2026, Shah Capital filed Amendment No. 8 to its Schedule 13D reporting that Shah Capital Management had filed a Form ADV-W to voluntarily withdraw its registration as an investment adviser with the U.S. Securities and Exchange Commission, and that the reporting persons (Shah Capital Management, Shah Capital Fund LLC, and Himanshu H. Shah) no longer held their Novavax shares with the purpose of influencing control and intended to report on Schedule 13G going forward. The filing attributed the change to a restructuring of Shah's investment-management activities into a newly formed family office, Himanshu Shah Family Office LLC. The amendment reported beneficial ownership of 10,656,964 shares, or approximately 6.46% of Novavax common stock.
By the Factrail desk · Method: how we source and score · Last reviewed
Related people
Related organizations
- Bank of Americanamed 7 times
- White Housenamed 6 times
- Thomson Reutersnamed 4 times
- Department of Health and Human Servicesnamed 4 times
- European Commissionnamed 4 times
- New Yorknamed 3 times
- Department of Defensenamed 3 times
- Goldman Sachsnamed 3 times
- Department of Justicenamed 3 times
- The Washington Postnamed 2 times
- The Sunnamed 2 times
Facts mentioned
Drivers named in the text
Linked because the text names them, not because anything was measured.
Indicator profile, not a rating
Built from the indicator links of the drivers this text names. A profile of coverage, not a score.